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1Introduction
Liver is the largest organ in human body. It plays vital role in many functions like protein
metabolism, detoxification, clotting factor synthesis and so on.
Liver dysfunction secondary to loss of hepatocyte function may be acute or chronic. Common
causes of liver dysfunction are, viral hepatitis, alcoholic liver disease, metabolic diseases
affecting liver and many a times it is cryptogenic.
Idiopathic Non Cirrhotic Intrahepatic Portal hypertension (NCIPH) is a common cause of
chronic liver disease in Indian subcontinent and is an obliterative portal venopathy as
documented in biopsy and explant livers. The cause of portal venular occlusion is poorly
understood
The pathogenesis of chronic liver disease is not well understood in case of cryptogenic liver
disease and recently number of studies has concentrated on this aspect. In our institution Non
Cirrhotic Intrahepatic Portal hypertension (NCIPH) was found in significant number (48%) of
patients with cryptogenic cirrhosis1. The major morbidity and mortality in chronic liver disease is
due to portal hypertension and its consequences.
Thrombocytopenia is common in patients with chronic liver disease with any etiology, is seen in
30-76% of patients2 and is multifactorial. It limits therapy in certain conditions and delays major
diagnostic and therapeutic procedures as risk of bleeding in these cases is high. Whether
thrombocytopenia is cause or effect of liver disease is not well understood.
Some causes proposed for thrombocytopenia in patients with chronic liver disease are splenic
sequestration, bone marrow suppression and decreased production of thrombopoietin..
2Studies have shown that patients with portal hypertension due to NCIPH or cryptogenic cirrhosis
have decreased ADAMTS13 level. ADAMTS 13  is a protease cleaving von Willebrand factor
(vWf). Due to ADAMTS 13 deficiency these patients  have increased ultra large von Willebrand
factor (UL vWF) in the circulation. It is hypothesized that the imbalance of ADAMTS 13 : vWf
can lead to increased platelet aggregation on to ULvWF and form platelet micro- thrombus
leading on to portal venular obliteration.3,4,5
Platelet counting is routinely done using automated counters using coulter principle and it can be
done manually also. A difference in coulter and manual platelet count is noted routinely in
practice.
We hypothesized that the difference in platelet count is secondary to platelet clumps which will
not be counted as platelets by automated counters leading to low platelet counts compared to
manual counts.
We aim to study the difference in manual and coulter platelet count in patients with cryptogenic
chronic liver disease with portal hypertension and to compare with those with hepatitis B or C
related chronic liver disease with portal hypertension, healthy controls and also those with extra
hepatic portal vein thrombosis, aplastic anemia, idiopathic thrombocytopenic purpura and
constitutional macrothrombocytopenia.
3Aim
Analysis of thrombocytopenia and endothelial dysfunction in patients with portal hypertension
Objectives:
Objective 1:
To analyze thrombocytopenia in patients with portal hypertension and in control groups of
patients (with thrombocytopenia due to other causes) by
a. Study of the difference between manual and coulter platelet counts in study subjects
b. Study of platelet clumping and immature platelet fraction in study subjects
Objective 2:
To analyze the impact of thrombocytopenia and of plasma von Willebrand factor (vWf)levels on in-hospital survival in patients with acute-on-chronic liver failure (ACLF).
4Platelets
Specialized blood cells discovered in 1882 by Giulio Bizzozero13 which play central role in
hemostasis. It plays important role in other functions like inflammation and tumor metastasis,
some studies have shown its role in wound healing and host defense also. Platelets are the
smallest of human blood cells with size 3.6-0.7µm. Megakaryocytes in bone marrow release it as
anucleated cells into the peripheral circulation with a life of 7-10 days. They are dynamic but
usually inactive and gets activated when blood vessel is damaged14
Normally only 2/3rd of total platelets are in circulation and the remaining stored in spleen.
Normal platelet count is 150-400 x 103/ µL. A healthy adult can produce 1011 platelets/ day and
old platelets are destroyed by Kupffer cells in spleen and liver15.
Platelets are anucleated but contain mitochondria, have plasma membrane made of lipid bilayer
which express various surface receptors and have lipid rafts which help in signaling and
intracellular trafficking. Platelets contain two major storage granules, alpha and dense granules.
These granules store biologically active molecules which initiate coagulation and recruit other
cells during inflammation.
Alpha granules are more prevalent and it contains GPIIbIIIa, fibrinogen and vWf which initiate
coagulation cascade and many membrane proteins essential for platelet function like P-selectin
(CD62P) and CD36. P selectins are known to recruit neutrophils. Dense granules store molecules
which are secreted during platelet activation like catecholamine, serotonin, calcium, ADP and
ATP. ADP helps in triggering platelet shape change, granule release and aggregation.
5Pathophysiology of portal hypertension
To better understand portal hypertension it is important to know portal circulation better first. It
is a unique system which connects two different capillary beds; capillary beds of the wall of the
small intestine and spleen to that in sinusoidal area of the liver.
The portal venous system directs blood from parts of the GI to the liver. Splenic and superior
mesenteric veins join behind the neck of pancreas to form portal vein. Inferior mesenteric vein
joins superior mesenteric vein just before it joins splenic vein. Portal vein also receives blood
from superior pancreaticoduodenal vein, left gastric (coronary) vein and the cystic veins directly.
Above veins play important role in portal hypertension and esophageal varices development.
These veins together drain majority of the gastrointestinal tract into portal vein which divides
into right and left branches entering corresponding lobes of the liver. Portal vein makes up 80%
of the total blood flow to liver and 20% of the oxygen supply playing crucial role in liver
function. Portal vein subsequently divides into smaller branches and ends up in hepatic
sinusoids. In hepatic sinusoids hepatic arterial blood mixes with portal venous blood and it
passes through sinusoids and then enters central vein and the blood from central vein drains into
hepatic vein and hepatic veins to inferior vena cava.16
Hepatic sinusoids are important and it makes up a large surface area in the liver which is covered
by a layer of endothelial cell. Endothelial cell encloses space of Dissse. The hepatic sinusoidal
endothelial cells are unique, they are fenestrated, the size of fenestrae is variable. The
subendothelial basement membrane permits free passage of substances through it as it does not
have intercellular junction.
The endothelial fenestration size varies in response to various stimuli, like changes in sinusoidal
pressure, circulating endotoxin, ethanol, serotonin and nicotine.
6Portal hypertension is a complication of liver cirrhosis which determines the natural history. In
the last few years significant progress has been made in understanding Pathophysiology of portal
hypertension. However some issues are still not clear and needs further studies. Portal
hypertension basically has two components, first is a fixed one i.e increased Intrahepatic vascular
resistance, second one is dynamic i.e increased splanchnic blood flow18.
The fixed component is mainly due to liver sinusoidal endothelial cells (LSEC’s) dysfunction.
Endothelial cells form the first line of defense in liver from injury. Sinusoidal endothelial
dysfunction is mainly due to hypoactive endothelial cells. 98% of the total endothelial sinusoidal
cell is comprised of LSEC’s. LSEC dysfunction leads to increased intrahepatic resistance in the
microcirculation leading to PHTN. 21
LSECs have multiple functions. It regulates blood clearance from liver vasculature by altering
vascular tone, it has role in immunity, hepatocyte regeneration, angiogenesis and sinusoidal
remodeling. Thus, LSEC dysfunction results in the liver cirrhosis due to enhanced fibrosis and
portal hypertension due to impaired vascular tone and in turn resistance.
LSEC’s ply important role in maintaining Intrahepatic vascular tone. Vasoactive products
secreted from the LSEC’s act on HSCs and causes contraction or relaxation. These vasoactive
products also regulate hepatic sinusoidal microcirculation.
Substances like ET-1, AT- II, nor epinephrine, PG- F2, TX-A2 can trigger contraction of HSCs.
In contrast, substances such as Ach, VIP, NO, CO, PG- E2, and adrenomedullin relax HSCs.
Among these agents, ET-1 and NO have been studied well and has been recognized as important
regulators in sinusoidal microcirculation. vasodilatation in the microcirculation is by stimulating
eNOS activity. Nitric oxide plays an important role in the vascular tone in the hepatic
microcirculation.17
7Studies have shown that in patients with cirrhosis, the liver fails to accommodate the increased
portal inflow like in that caused by postprandial hyperemia, it leads to an abrupt increase in
portal pressure. It is important because it determines the progression of varices in portal
hypertension.
Another important thing in cirrhosis is decreased NO production by the LSEC’S as mentioned
above leading to impaired vasodilator response. Increasing the NO availability in liver
microcirculation is a target in the treatment of portal hypertension.
Defenestration of LSEC’S and endothelial dysfunction as described above are the initial events
in the development of liver injury and as a result of  defective bidirectional exchange along the
endothelium, probably may play role in subsequent progression of the liver cirrhosis also20.
Causes of LSEC dysfunction:
Oxidative stress:
Oxidative stress can cause endothelial dysfunction. Cirrhotic patients have elevated
malondialdehyde levels in the circulation. It is an indicator of oxidative stress. Attenuation in
postprandial portal pressure and HVPG with vitamin C was noted in some studies22 pointing
towards the role of oxidative stress in pathogenesis of portal hypertension. eNOS activity is
impaired by oxidative stress by various mechanism.23,24
a. eNOS association with caveolin-1, which is is an inhibitor of eNOS
b. inhibition of ET-1 induced eNOS phosphorylation25
c. Dissociation of eNOS from ET-B receptor.26
Together all these leads to decreased NO production leading to endothelial dysfunction.
8Inflammation
Inflammation has a role in SEC dysfunction in liver cirrhosis patients. Caveolin-1 an eNOS
inhibitor is increased in response to endotoxins leading to decreased NO production. LSECs also
express TLR4 which is an endotoxin receptor which regulates angiogenic responses. It has been
postulated to enhance fibrogenesis leading to portal hypertension.28,29
Alcohol
Alcohol being an important cause of liver diseases has been implicated in LSEC dysfunction by
producing pro fibrotic factors. Acetaldehyde which is a metabolic product of ethanol forms
adduts with proteins and cause deleterious effects on LSEC’s. These adducts increases
fibronectin expression in the LSECs and promote fibrosis by stimulating HSCs. Other
mechanism like miRNA and shear stress a change at the microvascular level stimulate gene
expression in LSECs and promotes fibrogenesis.29
9Etiology of portal hypertension
The etiology of portal hypertension varies in different parts of the world. In the western world
leading causes are hepatitis C and alcohol. However in India the etiological profile is different.
Studies from our studies have shown slightly different etiological profile. A study including 583
patients including even the elderly population the most common etiology of portal hypertension
was cryptogenic cirrhosis 128 (35%) followed by, alcohol 155(29%), viral, hepatitis B and C
133(23%), vascular 56(10%) and others 28(5%)30. In children the etiological profile was
different. Extrahepatic portal vein obstruction (66%) was the most common cause of portal
followed by Intrahepatic causes like wilson’s disease (55%), autoimmune hepatitis (10%),
NCIPH (19%) and idiopathic (24%)31. However European countries have mainly Intrahepatic
cause of portal hypertension (~60%).32
Thrombocytopenia in chronic liver disease
In patients with CLD thrombocytopenia (platelet counts <150,000/lL) is common. Its incidence
varies from 30-76% in cirrhotic patients2. The significance of mild thrombocytopenia is minimal
and it does not interfere with routine treatment or management decisions. So also, moderate
thrombocytopenia which is noted in approximately 13% of CLD patients. Severe
thrombocytopenia (<50,000/lL) in advanced CLD may interfere in treatment decisions and be
associated with significant morbidity. Mild to moderate thrombocytopenia usually is
asymptomatic and it does not have any consequences, but invasive procedures like liver biopsy
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and LTX carries significant risk of bleeding in severe thrombocytopenic. Intra cerebral
hemorrhage or GI bleed (non variceal) is rare but can be fatal.33
Platelet play a very important role in liver regeneration as a source of serotonin and many studies
have shown this fact recently in animal models and in post partial hepatectomy settings.
However weather thrombocytopenia widely observed in chronic liver disease is cause of or
effect of liver disease is not well defined.
Causes of thrombocytopenia in patients with liver disease
Thrombocytopenia in liver disease is common and causes are many33. Proposed causes are
a. Increased splenic sequestration of platelets (hypersplenism)
b. Suppression of bone marrow platelet production
c. Decreased activity of thrombopoietin, hematopoietic factor for platelets
Historically, thrombocytopenia in liver disease has been attributed to hypersplenism. But is not a
well established cause till date. Many CLD patients with normal spleen size have low platelet
counts and even the therapies aimed to reverse the same have not yielded consistent result
questioning the role of enlarged spleen alone as the cause of thrombocytopenia and even other
cytopenia’s noted in liver disease patients. This finding prompted to think of alternative causes
for cytopenias. Proposed causes are exaggerated intrasplenic cell destruction, autoantibody
production by spleen and hemodilution secondary to plasma.
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Increased splenic sequestration of platelets (hypersplenism)
In 1942 Wiseman and Doan" described, for the first time, a syndrome characterized by
neutropenia, an enlarged spleen, and a bone marrow that was normal in its capacity to produce
this type of cell. They originally termed this syndrome primary splenic neutropenia. it is
important to know normal splenic anatomy and function to better understand hypersplenism.
Spleen has a capsule which sends trabaculae into the parenchyma. The capsule and trabaculae
contain smooth muscles and they contract and relax in response to sympathetic inputs. Once
blood enters spleen it flows sluggishly through splenic pulp and then enters venous sinuses. It is
here in these sinuses blood cells come in contact with reticulo-endothelial system and the old and
worn out cells gets destroyed. Spleen has three important functions normally. To destroy red
blood cells, to store blood and to produce lymphocytes. In hypersplenism, apparently there exists
a pathologic increase of this normal function.37
Kracke has stated that four premises must be established before the diagnosis of hypersplenism
can be made. (1) Palpable spleen (2) decrease in the circulating cellular elements of the blood
including neutropenia, thrombocytopenia, anemia, or various combinations of these; (3) a
hyperplastic/normal bone marrow; and (4) demonstration of splenic over-activity by the
epinephrine test. However in some rare cases spleen may not be enlarged and this does not rule
out hypersplenism.
In hypersplenism cytopenias noted is due to increased destruction of the cells or is just trapped in
spleen leading to peripheral cytopenias is not established. As mentioned above some studies have
shown increased  intrasplenic antibodies which may be the cause of cytopenias in hypersplenism
cases, however antibodies have been shown to be against platelets only, then explaining cause of
pancytopenia in hypersplenism will be difficult with this theory.
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There is no established direct relationship between size of spleen and severity of hypersplenism.
The specific mechanisms by which the spleen traps cells that are so slightly altered as to escape
destruction elsewhere in the reticuloendothelial system are not fully understood; in large part,
however, the filtration appears to result from physical alterations in the cell, particularly  changes
in size and shape (which includes agglutination), in viscosity (or rigidity) and probably in the ill-
defined property of surface stickiness. studies by Cohen, Gardner and Barnett'6 in patients with
congestive splenomegaly and thrombocytopenia revealed very little diminution in platelet
survival. Thus, despite the remarkable capacity of the spleen to sequester and destroy slightly
altered or abnormal cells, and even despite the fact that this filtering capability is increased by 2-
or 4-fold in patients with splenomegaly, including those with congestive splenomegaly, this need
not bear upon the hypersplenic state. Human studies with Cr51 shows that in normal human
beings the red blood cells reaches an equilibrium in 2 min after intravenous injection. Taking
into consideration the arm-to-spleen circulation time and systernic mixing it appears that the
transit time averages no more than about 30 seconds, with an upper limit of about 1 minute. In
most patients with splenomegaly, regardless of cause, the Cr51 mixing pattern is quite different
and frequently shows two distinct components.
While a rapid, nearly normal-mixing component accounts for from 50 to 80% of the splenic
radioactivity, a second, slower component emerges having a half-time of as long as 20 or 30
minutes and resulting in a delay in the turnover time which may exceed one hour in patients with
very large spleens. Contemporaneously, of course, the quantity of labeled cells in the circulation
continues to decline. Portal hypertension is a common cause of splenomegaly and
hypersplenism, and one may reasonably speculate that its mechanism involves the hydrostatic
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displacement of intrasinusoidal red cells into the slow-flowing cordal passages by forcing them
through the basement membrane or by retarding their return to the sinuses.
Experimental studies also have shown that in those patients with hypersplenism the splenic
sequestration is associated with decreased survival of blood cells to certain extent.
Stasis of cells in the splenic cords leads to metabolic stress as they are tailored for normal
circulation period in the spleen otherwise.
Another important situation is with reticulocytes. These immature red cells, particularly the
youngest of them, are somewhat selectively concentrated in the spleen, probably by virtue of
their larger size and their sticky surfaces. The same may hold good in case of platelets also.
Penny et al. harvested all the platelets they could from operative spleens by various perfusion
methods; their direct counts of platelet numbers and Aster's kinetic studies agree rather closely
with respect to the magnitude of platelet pooling, and show that the sum of circulating and
splenic platelets in hypersplenic thrombocytopenia usually represents a normal total platelet
mass.
From the foregoing it is clear that in man the normal spleen has little reservoir function with
respect to red cells and granulocytes, but does contain a relatively large, moving pool of
platelets, about 25-30% of the total, and perhaps one-third of the total lymphocyte population. In
many animals, and possibly in man, the platelet pool enlarges during sleep, and discharges
during excitation. From the standpoint of maintaining blood fluidity during the slowed
circulation of sleep, a lowering of blood hematocrit, platelet levels and plasma coagulability
through splenic pooling presumably serves a valuable physiological purpose.
Hypersplenism, for the most part, represents an exaggeration of the actual or potential capacity
of the spleen to pool blood elements.
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The thrombocytopenia which results from extensive pooling may heighten the hazard of massive
bleeding and may potentiate other haemostatic defects, but it alone is not usually a cause of
dangerous purpura and the spleen pool presumably does contract during bleeding so as to make
available the functional platelets therein.
However there are certain findings which argue against this theory i.e even after splenectomy
thrombocytopenia is not completely reversed in some cases, so also with splenic artery
embolisation. 25% of cirrhotic patients with normal spleen size have low platelet count and
conversely, 19%–29% of cirrhotic patients with splenomegaly were found to have normal
platelet counts. So, splenic pooling alone can’t explain thrombocytopenia in cirrhotic patients.
Decreased thrombopoietin production
Thrombopoietin is a glycoprotein hormone produced by liver mostly which acts as a growth
factor on megakaryocytes to regulate platelet production. In advanced liver disease the synthetic
functions of liver are compromised so also thrombopoietin production. This is supported by the
fact that TPO expression in liver is constitutive and is not regulated at the level of transcription.
Platelet count regulates plasma TPO levels and is inversely correlated34. A recent study has
shown that platelets which are old and about to get destroyed stimulates thrombopoietin
production and in turn replenishes the platelet pool.
In patients with low platelet count with normal liver function, TPO level ranges from 600-2900
pg/ml. In patients with advanced liver dysfunction have significantly low TPO levels in plasma.
The evidence in favor of this has come from those who undergo liver transplantation. In patients
with liver transplantation plasma TPO level and platelet count significantly increases by post op
day 14. Similar findings are not seen in patients who undergo TIPSS for portal hypertension
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complications even though HVPG decreases significantly. These two findings suggest that
deficiency of TPO drives thrombocytopenia. However other cytopenias seen in significant size
of patients can’t be explained with TPO deficiency alone.
Initial findings from some studies have shown 30-40% reduction in thrombopoietin mRNA
content in the liver in patients with liver disease compared to those without liver disease.
Beside a decreased TPO production, there is also an increased TPO breakdown in cirrhosis.
There are certain studies with conflicting results in relation to TPO level in patients with
cirrhosis.
Suppression of bone marrow platelet production
Decreased bone marrow production is supposed to be one of the cause for thrombocytopenia in
patients with cirrhosis. It may be due to the etiology of liver disease like in those with ALD and
in hepatitis C related cirrhosis as shown in certain studies or it may due to idiopathic bone
marrow dysfunction or exhausted bone marrow secondary to long standing liver disease.
G Stiegler et al looked at TPO level, platelet count and reticulated platelets in patients with liver
cirrhosis pre and post LTx and found that all patients except one were thrombocytopenic and
TPO level was in the normal range prior to transplantation and it increased by 5 fold on post
transplant day 5. Platelet count decreased till day 5 even though reticulated platelets increased
from day 2 post LTx till day 6. When platelet count got normalized reticulated platelet count was
also normal. This provided evidence for an augmentation in de novo platelet production post
liver transplant.
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However bone marrow suppression may have only minor contribution towards
thrombocytopenia in cirrhotic patients.
Hemostasis rebalances in liver disease
Hemostatic system changes are frequently encountered in liver disease patients. Common
changes encountered are low platelet count, functional defects of platelets, decreased coagulation
factors and inhibitors and decreased fibrinolytic proteins. As a consequence routine tests of
coagulation like PT, aPTT and platelet count are abnormal frequently. Usually in normal tests
abnormalities of these tests would ofte due to complex hemostatic changes.
In recent years, the traditional concepts of hemostatic disorders and its clinical consequences
have dramatically changed. In particular, the concept of hypocoagulability in liver disease has
changed. Abnormal routine coagulation tests may not always indicate increased bleeding risk
and these patients in contradiction may be prone to thrombotic disorders.
For example, platelet number and function defects have been balanced by vWf- ADAMTS13
imbalance. The net result is enhanced platelet clumping in invitro testing. Endothelial changes,
which have been not studied in detail in liver disease may play central role in hemostatic
rebalance. This aspect needs further exploration.
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Factors causing hemostatic rebalance in patients with liver cirrhosis40
Changes-antithrombotic Changes –prothrombotic
Low platelet count Elevated levels of vWf
Defective platelet function Decreased levels of ADAMTS13
increased production of PG and NO Increased factor  VIII level
Decreased coagulation factor levels Low  protein C and S, antithrombin III level
Deficiency of vitamin K
Decreased fibrinogen level Decreased  plasminogen level
Elevated t-PA levels
vWf- von Willebrand factor, t-PA- tissue plasminogen activator, PG- prostaglandin, NO- nitric oxide,
Procoagulants
Anticoagulants
18
Endothelial dysfunction in liver disease
Endothelial dysfunction plays very important role in portal hypertension and liver disease
pathogenesis. In portal hypertension role of LSEC dysfunction and stellate cell activation has
been explained in detail in previous sections of the review.
Next much less explored important component is ADAMTS13 and von Willebrand factor
imbalance. Whether it has causative role in liver disease primarily or is a secondary outcome of
endothelial dysfunction is not yet well understood. However, of late many studies have tried to
understand the role and/ or effect of this imbalance in patients with liver disease.
ADAMTS13 is a metalloproteinase it specifically cleaves large VWF between two residues
(Tyr1605 and Met1606). Absence of ADAMTS13 activity leads to defective cleaving of
ULVWFMs which are released from vascular ECs leading to accumulation of ULVWFMs which
can induce platelet micro thrombi formation under shear stress.3
Currently, a severe deficiency of ADAMTS13 activity is noted in those with genetic mutations
of ADAMTS13 gene, as in Upshaw- Schulman syndrome 41 or due to autoantibodies produced
against ADAMTS1342 as in TTP. Analysis has shown that ADAMTS13 mRNA is highly
expressed in the liver43 is produced exclusively in HSCs. Even though Platelets, vascular
endothelial cells, and podocytes of kidneys have been implicated as ADAMTS13-producing
cells, the amount produced by them appears to be far less than that by HSCs.
ADAMTS 13 levels have been noted to be significantly low in patients with alcoholic hepatitis,
veno occlusive disease, advance liver cirrhosis, non cirrhotic intrahepatic portal hypertension,
those undergoing LDLT and post partial hepatectomy.
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Vascular endothelial cells play central role in hemostasis and thrombosis41. Von Willebrand
factor, is a marker of endothelial cell damge/ activation. In injured liver due to necro-
inflammatory process SCEs shows positivity to vWf which otherwise is not expressed in normal
liver cells. Along with this capillarization of hepatic sinusoids is also noted44
Subsequently, increased levels of UL-VWFM mediates platelets adherence to to subendothelial
tissue . Normally ADAMTS13 then cleaves it into smaller VWF multimers 45, essentially the
initial step in hemostasis.
In patients with liver dysfunction, plasma VWF levels are high 46. In an autopsy series one half
of the patients had shown microthrombi in one or multiple organs 47 Such a imbalance leading to
hypercoagulable state in liver diseases may lead to hepatic parenchymal extinction and may
accelerate liver fibrosis and in turn disease progression. Subsequently it will end up in
complications like HRS, HPS, port pulmonary hypertension, and SBP which are the main causes
of mortality in advanced liver disease.
As ADAMTS13 is synthesized in hepatic stellate cells and its substrate, UL-VWFM in the
transformed SEC as a result of liver injury, ADAMTS13/vWf imbalance cause sinusoidal
microcirculatory disturbances, add to subsequent progression of liver diseases and terminates in
multiorgan failure.
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Relation between thrombocytopenia and ADAMTS 13 and vWf imbalance
It is well accepted that thrombocytopenia progresses as with advancing liver dysfunction.2
Thrombocytopenia in liver disease is caused by multiple factors as discussed in detail in above
section.
Recent studies have provided insight in this aspect. In patients with advanced cirrhosis, increased
ULVWFM enhances platelet aggregation and it results in thrombocytopenia.48
Platelets have recently been shown as a driver of liver injury in animal models of viral hepatitis.
It can promote liver regeneration through intra-platelet serotonin. In spite of their emerging role
in those with inflammatory liver disease, not much is known about the mechanisms by which
thrombocytes bind to the hepatic vasculature.
Recently it has become apparent that platelets can, under some circumstances, bind to
endothelial cells, where they can support leukocyte recruitment to the vessel wall 48
In L-selectin- deficient mice, activated platelets can reconstitute P-selectin-dependent
lymphocyte homing to lymph node high endothelial venules 49. Hepatic endothelial cells fail to
express P-selectin even when inflamed, and a similar mechanism could provide a P-selectin
substrate within hepatic sinusoids in the absence of endothelial P-selectin51. Platelets are
sequestered in the liver following experimental transplantation 51 and correlate with graft
survival. Similarly increased binding of platelets to sinusoidal endothelium and enhanced
neutrophil recruitment is observed in mice exposed to LPS and following I/R injury, and serum
from cirrhotic patients contains elevated levels of von Willebrand factor (vWF) and promotes
platelet binding to collagen.
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Mechanism of decreased ADAMTS 13 levels in liver cirrhosis
The mechanism responsible for the decrease in ADAMTS13 in advanced liver disease is not
clear. Causes may include enhanced consumption by vWf degradation, inflammatory
ADAMTS13 plasma inhibitor or cytokines released secondary to inflammation52
It is controversial whether decreased ADAMTS13 level is due to decreased production in the
liver or due to liver dysfunction. Alternatively, some studies have shown role of cytokinemia53,54
and endotoxemia as additional potential candidates. Investigations have demonstrated that IL-6
inhibited the action of ADAMTS13 under flow conditions and both IL-8 and TNF-α stimulated
the release of UL-VWFM in human umbilical vein endothelial cells in vitro. In addition,
ADAMTS13 deficiency associated with inflammation promoted formation of UL-VWFM , and
intravenous infusion of endotoxin to healthy volunteers caused a decrease in plasma
ADAMTS13 together with the appearance of UL-VWFM.
As systemic inflammation is an important drive for ADAMTS 13 and vWf imbalance which may
promote platelet adhesion to endothelium leading to microvascular thrombosis and multi organ
dysfunction with very grave prognosis.
We studied vWf level in patients with ACLF, a condition with high systemic inflammatory state
with high short term mortality rate.
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Acute-on-chronic liver failure (ACLF)
Liver failure is a common condition and recently its incidence is increasing with increasing use
of alcohol and increasing incidence of obesity and diabetes. It has a spectrum of presentation. It
can be ALF if there is no preexisting liver disease, ACLF, acute deterioration in those with
known or unknown prior liver disease, or as an acute decompensation of ESLD.
ACLF is a syndrome in which acute and severe hepatic derangement results from various insults.
This term was first came to use in 1995 to describe a condition in which two insults were
operating in liver simultaneously. One being chronic which is ongoing and the other acute. These
patients are uniquely different from acute worsening of DCLD in which liver failure is central as
against ACLF in which extrahepatic organ dysfunction plays central role.9
Definition of ACLF
APASL consensus statement defines ACLF as an acute hepatic insult manifesting as jaundice
(serum bilirubin ≥5 mg/dl ) and coagulopathy (INR ≥1.5 or prothrombin activity <40 %)
complicated within 4 weeks by clinical ascites and/or encephalopathy in a patient with
previously diagnosed or undiagnosed chronic liver disease/ cirrhosis, and is associated with a
high 28-day mortality.9
However there are many more definitions for ACLF. One of the important among them is EASL-
AASLD consortium definition which defines ACLF as acute deterioration of pre-existing, CLD,
usually related to an acute precipitating event which is associated with increased mortality at 390
days due to MOF.
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Epidemiology
In Asian countries the common acute events are flare of hepatitis B, acute hepatitis E, alcohol,
drug induced specifically ATT. Underlying chronic liver diseases are ethanol or hepatitis B
related and then cryptogenic liver disease. In western countries this varies. Bacterial infection,
variceal bleed, alcohol are the important acute precipitating factors. Hepatitis C and ethanol
related liver disease are important causes for underlying chronic liver disease.
ACLF flow diagram9
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Sepsis is important in patients with ACLF. It plays important role in inflammation and imbalance
of innate & adaptive immune responses in ACLF. It is very difficult to differentiate SIRS and
early sepsis in cirrhotic patients. Identifying infections in cirrhotic patients at the earliest and
initiation of appropriate antibiotics is helpful in treating sepsis, organ failure, and inturn
mortality. Sepsis in a patient of ACLF has very high mortality due to MOD.
PIRO concept in acute on chronic liver cell failure- pathophysiology
ACLF carries very high short term mortality to the tune of 46- 89%. However, Pathophysiology
is not well understood. The main cause for high mortality rate has been shown to be associated
organ dysfunction in ACLF. Understanding Pathophysiology is key to improve survival in these
patients.56
The pathophysiology of ACLF can be explained using the PIRO concept. It was initially
developed for use in the sepsis setting. Using this concept in ACLF, in which ‘P’ stands for
predisposition: predisposing factors which make a cirrhotic individual more likely to develop
ACLF and organ failure. ‘I’ stands for acute insult or precipitating event, ‘R’ stands for
inflammatory/immune response, which is a consequence of the acute insult. ‘O’ signifies organ
dysfunction, which is the final sequelae of the inflammatory response generated following the
acute insult. These four could represent the most important factors determining outcome in
ACLF.
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As determined by various prospective studies the important predisposing factors determined are
Male gender
Higher bilirubin level
Lower albumin level
Higher Child-Pugh (CTP) and MELD score
Hospital admission in the preceding six months with hepatic decompensation.
However the above mentioned factors may not help in predicting survival in ACLF one organ
failure develops. The literature suggests that once extrahepatic organ failure sets in, then organ
failure scores 55such as the Sequential Organ Failure Assessment (SOFA) or the Acute
Physiology, Age, and Chronic Health Evaluation (APACHE) may be more useful in predicting
outcome and survival.
In the majority of patients, ACLF usually develops following an identifiable precipitating event.
These precipitants may directly affect the liver or may be a consequence of an extrahepatic
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insult. The most common precipitating event in ACLF is infection. According to the literature, it
accounts for up to 47% of all precipitating events.
Precipitants may be hepatic, like- alcohol, acute viral hepatitis A,B,E, drug, portal vein
thrombosis, ischemia hepatitis, non hepatotropic viral or bacterial infections or Extrahepatic,
like- surgery, trauma.
Sepsis and variceal bleed are also considered as acute insult in certain definitions.
Inflammatory response follow the initial insult, there is an altered host response to injury,
resulting in excessive systemic inflammatory response. This altered response induces tissue
damage and subsequent organ failure. Dysregulated inflammation is considered a hallmark of
ACLF and the mechanism by which this arises is multifactorial. Hyperdynamic circulation is a
common aspect in patients with systemic inflammatory response syndrome. In these patients
with enhanced cytokine production, there are severe disturbances of the cardiovascular system:
the circulation becomes hyperdynamic, cardiac output increases, and both blood pressure and
systemic vascular resistance decrease. In cirrhotic patients, in addition to the precipitating insult
there is increased bacterial translocation, secondary to increased intestinal permeability and
changes in intestinal microflora which add to the inflammatory response. Despite the insult
ACLF patients fail to generate adequate immune response due to defect in the innate immune
system.  In patients with ACLF, the Kupffer cells are bypassed due to presence of both intra and
extrahepatic shunts, leading to defective clearance of endotoxins. In addition,reduced protein
synthesis  in cirrhosis results in defective complement production. This leads to decreased
opsonisation capacity of the Kupffer cells and thus, bacterial phagocytosis is impaired.3 Another
contributing factor to altered host response in ACLF is a phenomenon known as “immune
paralysis”, as in sepsis, and is associated with a high mortality.
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In ACLF patients, reduced HLA-DR (antigen-presenting receptor complex on peripheral
monocytes) expression and decreased TNF-α production following stimulation with LPS is
noted.
Dysregulated immune system in ACLF following an initial response shows an exaggerated host
response with release of proinflammatory cytokines in to the circulation. This leads on to
systematic inflammatory response syndrome (SIRS). Increased incidence of organ dysfunction
(hepatic encephalopathy, acute kidney injury and bacterial infection) is noted in patients with
SIRS. Presence of SIRS predicts poor survival as studies have shown that in ACLF, SIRS
incidence was high among those who did not survive an episode of ACLF than those who
survived.
Along with micro circulatory dysfunction dysregulated innate immune system promotes macro
circulatory dysfunction also. Hemodynamic changes in ACLF leads to hyper dynamic circulation
and decreased systemic vascular resistance leading to end organ hypo perfusion, SIRS along with
end organ hypo perfusion lead to multi organ dysfunction.
Approximately 33% of patients with ACLF develop organ dysfunction and it has an important
role in the natural history, morality/morbidity. Following the development of organ failure,
mortality steeply increases. Other than liver, kidneys, brain, adrenals and circulatory system are
also commonly affected.
Endothelial dysfunction in ACLF
As mentioned above deregulated inflammatory response is characteristic in the setting of ACLF.
Severe inflammation is an important stimulant for stellate cells and liver sinusoidal endothelial
cells (LSEC’s). Deregulated inflammatory response may act as an important drive for vWf
secretion in the endothelial cells. As mentioned above in the pathogenesis of portal hypertension
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and thrombocytopenia patients with liver cirrhosis are known to have low ADAMTS 13 level
and inflammation further inhibits secretion of the same. In the background of decreased
ADAMTS 13 level, increased vWf levels may prove detrimental leading to microcirculatory
thrombus in which platelets may play important role and hence organ dysfunction, a form of low
grade TTP. There is some indirect evidence for this hypothesis. Correlation has been established
between severity of inflammation, organ dysfunction and survival in recent studies.
In a recently published abstract by R Garcia Martinez et al82 endothelial dysfunction was studied
by measuring vWf and NO levels and a good correlation was found between the level of these
markers of endothelial dysfunction and organ dysfunction and so also decrease in the level of
these markers with albumin infusion as the organ dysfunction improved.
Defining liver failure in ACLF:9
The two main variables in defining liver failure are bilirubin and coagulopathy. Bilirubin of
>5mg/dl is considered as cutoff in APASL guideline and ≥12 mg/dl in CANONIC study.
Coagulopathy is an important hallmark of liver failure. INR cutoff to define liver failure in
ACLF is taken as >1.5 by APASL and >2.5 in CANONIC group. It has been reported that
platelet count inversely correlates with ACLF grade.
Conventionally hepatic failure is defined by the onset of clinical ascites and/or encephalopathy.
However, both are not commonly seen patients with ACLF, and hence, the presence of one of
them can define ACLF.
SOFA appears to be good prognostic model in ACLF patients in ICU setting with critical
illness.
These patients with ACLF have very high 28 day and 90 day mortality. Most of the studies have
shown about 30%-35% 28 day mortality and 50%-60% 90 day mortality. Hence it is very
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important to recognize this at the earliest and start appropriate therapy and to prevent organ
dysfunction and intern mortality.
ACLF outcome
As per CLIF-EASL consortium study mortality it varied according to the grade in turn the
number of organ dysfunction. In those with no organ dysfunction 28 day mortality was 4.7%, 90
day mortality was 14%. With grade 1, 28 day mortality was 22.1% and at 90 day it was 40.7%.
with grade 2, 28 day mortality was 32% and at 90 day 52.3%. in grade 3, 28 and 90 day mortality
was7 6.1% & 79%.11
Overall in ACLF short term mortality varies from 30-90%. In hospital mortality is up to 53%.90
Treatment of ACLF 9
Treatment of ACLF will be based on the underlying cause. In those with hepatitis B flare oral
antivirals are effective. Urgent liver transplantation to be considered in those with severe liver
failure, i.e MELD >30. Organ failure by itself should not be a contraindication for liver
transplantation. Only if high cardiac or pulmonary support is needed or if they have rapidly
progressing organ failure at day 4 or 7 liver transplant may be a contraindication.
Liver dialysis like MARS and PROMETHEUS has been attempted with some success in some
studies, but needs further studies before being routinely used.
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Immature platelet fraction (IPF)
Immature platelet fraction is a novel parameter which measures reticulated, young platelets in the
peripheral blood. IPF increases as the production of platelets increases in the bone marrow. It is a
simple, indirect measure of bone marrow productive function in thmbocytopenic patients, in a
similar way to how reticulocyte count provides measurement of red blood cells production.57
Measurement of IPF may be a useful in distinguishing causes of thrombocytopenia. In case of
peripheral platelet destruction as in immune thrombocytopenic purpura, hypersplenism and
thrombotic thrombocytopenic purpura where in IPF will be increased in comparison to those
with bone marrow suppression or failure like aplastic anemia or chemotherapy induced bone
marrow suppression where in IPF will be low. This may even be used as a guide for platelet
transfusion requirements in certain clinical situations.
Circulating immature platelets, immature platelet fraction (IPF), is the term that defines much
larger platelets that have been recently released from the bone marrow. IPF measurement is
based on fluorescent flowcytometry principle, IPF have a much greater RNA content, and will be
measured by automated analyzers which has a reticulocyte detection channel, and then are
reported as percentage of the total platelet count (%-IPF).
Various studies have shown normal range as 0.5 to 5.2%, 1.1 to 6.1%, 0.5 to 3.2 %. Normal
ranges as per an Indian study were 0.7- 4.3%.
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Thrombocytopenia in liver disease is caused by multiple factors. One among them is
hypersplenism. In this case the IPF is expected to be higher in comparison to healthy controls as
bone marrow production will be normal with excessive peripheral destruction as in immune
thrombocytopenic purpura.39
In the setting of sepsis studies have shown that IPF can predict onset of sepsis and so also the
severity of sepsis, so it can be a better, cost-effective useful marker of sepsis which can be easily
done in all settings.
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Constitutional macrothrombocytopenia (CMT)
Constitutional macrothrombocytopenia is an uncommon disorder characterized by
thrombocytopenia, giant platelets, with normal platelet function and absence of any bleeding
symptom. It is also called Harris platelet syndrome. It is an autosomal dominant inherited
disorder. Till date few studies have been published in this disorder and it shows typical
geographic distribution of this disorder. It is common in the north eastern India, Nepal, Bhutan
and Bangladesh. An SNP of a gene with similar functions as MYH9A has been detected by some
investigators and it has been considered as a causative factor.89
Mediterranean macrothrombocytopenia is documented among the northern and Mediterranean
origin European population which is a similar condition. It is described as a disorder with large
platelets without any specific diagnostic clinical feature. It has been attributed to a defect in the
demarcatory membrane system of megakaryocytes by which the megakaryocytic cytoplasm
divides and forms a few larger blushed platelets preserving the overall platelet mass almost
normal.88
In a publication by our institution including healthy blood donors, it was noted that patients
specifically from West Bengal had macro thrombocytopenia and were asymptomatic and their
bleeding and clotting factors were normal. Total 78 patients from WB were included in this study
and 2.6% of them had severe thrombocytopenia, 11% had moderate thrombocytopenia and
18.8% had mild thrombocytopenia. When compared to healthy donors from Tamil Nadu, 80% of
the West Bengal donors had giant platelets (MPV-10 fL (7.5-16.8 fL). Where in Tamil Nadu no
patient had this.8
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Aim:
Aim: Analysis of thrombocytopenia and endothelial dysfunction in patients with portal
hypertension
Objective 1:
To analyze thrombocytopenia in patients with portal hypertension and in control  groups of
patients (with thrombocytopenia due to other causes) by
a. Study of the difference between manual and coulter platelet counts in study
subjects
This was a prospective observational study. The patients were recruited in the study from
November 2013 to January 2014. Patients with cryptogenic chronic liver disease CLD with
portal hypertension including non cirrhotic Intrahepatic portal hypertension (NCIPH) were
included as cases. Control groups had patients with hepatitis B or C related CLD with portal
hypertension, extrahepatic portal vein obstruction (EHPVO) with portal hypertension, aplastic
anemia, idiopathic thrombocytopenic purpura (ITP), constitutional macrothrombocytopenia
(CMT) and healthy volunteers.
The study was approved by Institutional Review Board (IRB) of Christian Medical College,
Vellore. Patients with age less than 18 years and those who did not provide consent for the study
were excluded from this study.
Cases and controls with liver disease were recruited from Liver clinic or Hepatology inpatient.
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Diagnosis:
Cryptogenic cirrhosis: Cryptogenic CLD was diagnosed when the etiological workup of
chronic liver disease (ANA, serum ceruloplasmin, 24 hr urinary copper level, viral serology, iron
studies) was negative
Non Cirrhotic Intrahepatic Portal Hypertension (NCIPH) was diagnosed as per following
criteria 4
 Portal hypertension (as evidenced by gastro-esophageal varices on upper
GI endoscopy)
 Patent portal vein and hepatic venous outflow tract
 Absence of advanced fibrosis (cirrhosis/ bridging fibrosis) on liver biopsy
 No evident etiology of chronic liver disease (e.g. alcohol, Hepatitis B/C)
 No lesion which can mimic NCIPH on biopsy (e.g. sarcoidoisis,
congenital hepatic fibrosis)
Portal hypertension was documented in all cases and appropriate controls in the presence of
esophageal and/or gastric varices on esophagogastroduodenoscopy (OGD).
Hep B and or C related CLD with portal hypertension: CLD as per the clinical, radiological
and biochemical features and portal hypertension as evidenced by gastro-esophageal varices on
upper GI endoscopy
Idiopathic Thrombocytopenic Purpura (ITP): was diagnosed based on history: Isolated
bleeding symptoms consistent with thrombocytopenia without constitutional symptoms, Physical
examination: Bleeding symptoms in the absence of hepatosplenomegaly, lymphadenopathy, or
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stigmata of congenital conditions Complete blood count: Isolated thrombocytopenia (platelet
count <100 x 109/L). Anemia only if due to Significant bleeding—otherwise normal red cell
indices, white blood cell count and differential. Peripheral blood smear: platelets normal to large
in size. Red and white blood cell with normal morphology6
Aplastic anemia: was deﬁned as pancytopenia with a hypocellular bone marrow in the absence
of an abnormal inﬁltrate and with no increase in reticulin7
Patients with ITP and aplastic anemia were recruited from Hematology department who attended
OPD for evaluation
Constitutional macrothrombocytopenia: asymptomatic mild to moderate thrombocytopenia i.e
platelet count 50-150x 109 /L with increased mean platelet volume (MPV>13) found during
routine evaluation in the absence of any significant disease8
Extrahepatic portal vein obstruction: extrahepatic portal vein obstruction was diagnosed on
colour doppler which showed chronic occlusion of the extrahepatic portal vein with or without
involvement of splenic vein, superior mesenteric vein with or without portal cavernoma with
esophageal and /or gastric varices documented on OGD
Platelet count and clumping:
Two blood samples, one with EDTA and another citrated were collected from the cases and
controls. Platelet counts, both manual and coulter, mean platelet volume (MPV) was done in all
these samples within four hours of collecting samples.
Platelet clump counting was also done by using the smear prepared from both samples.Number of platelet clumps per HPF was noted.
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Manual Platelet Count:
The test was performed on a venous blood sample collected using evacuated tube system and
anticoagulated with K2EDTA & citrate. The Platelet diluting fluid used was Fromal citrate
solution (1% Formalin in a 3% solution of trisodium citrate to which is added 1-2 drops of 1%
Brilliant cresyl blue stain). The diluting fluid was stored in a refrigerator prior to use. 20uL of
well mixed venous blood was diluted with 1.98 mL of diluting fluid to give a 1:100 dilution.
This sample was mixed well for 10 minutes. The improved Neubaeur chamber was then charged
and kept covered in a moist chamber for 10 minutes prior to performing the count.
The platelets were counted with a high dry objective (40x) and 10X eyepiece (combined
magnification of 400x) where the platelets are seen as refractile particles in the chamber. All
platelets in the large central square were counted. At least 100 platelets were counted. If the
central square did not yield 100 platelets another additional large square was counted.
Calculation:
Platelets/uL = No of platelets counted x dilution x depth
Area
Usual dilution: 1:100
Standard depth: 1/10 mm
Area counted: 4 sq mm (4 corner WBC squares)
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Automated Platelet count - Impedance method (coulter count)
Automated platelet count was performed using the Beckman Coulter DXH 800 (Beckman
Coulter Inc, Hilaeah, FL, USA). Peripheral venous blood anticoagulated with K2EDTA& citrate
was used for this analysis and the samples were analyzed in the primary mode (samples aspirated
by cap piercing method after positive identification by the analyzer) and the platelets were
enumerated using the impedance principle where the resistance created by the platelets passing
through an aperture in an isoelectric medium is converted into pulses that are directly
proportional to their size. The numbers of platelets were derived from the transformed data
resulting from the count of pulses generated in the impedance channel using the DXH Software.
Mean platelet volume was also obtained with the same machine in the same samples.
Corrected difference in platelet count (CDPC)
It was calculated using formula, CDPC=manual platelet count-coulter platelet count/coulter
platelet count. This was to avoid inadvertent difference between manual and coulter platelet
count due to difference in total platelet count in different groups, specifically healthy controls
who had normal platelet count.
The platelet counts were performed by 2 experienced Technicians in department of Transfusion
Medicine, who were not aware of the clinical diagnosis of each study subject.
Objective 1:
b. Study of platelet clumping and immature platelet fraction in study subjects
During manual platelet counting platelet clumps were looked for in both EDTA and citratesamples. The method for manual counting has been explained above in objective 1.
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To study the immature platelet fraction in different study groups
Immature platelet fraction was studied using five groups of patients. This was done prospectively
from January 2015 to March 2015. Cases included those with cryptogenic liver disease with
portal hypertension and controls included hepatitis B or C related chronic liver disease with
portal hypertension and healthy controls. Patients with aplastic anemia and ITP were also
included in the study but the number was very low.
We recruited 23 cases of cryptogenic CLD with portal hypertension, 14 HBV/HCV CLD with
portal hypertension and 19 healthy controls. 2 cases each of aplastic anemia and ITP were also
included after taking consent. All the cases and controls were defined as explained in objective 1
From each study subject 2ml blood was collected with vaccutainer in EDTA tubes and was
transferred to clinical pathology within 2 hours at room temperature.
IPF was measured using the Sysmex XN-9000 (Sysmex). It is a fully-automated hematology
analyzer employing flow cytometry and a semi-conductor diode laser system to analyze
leukocytes, nucleated red cells, and reticulocytes (RET channel) in the RET channel. Two
fluorescent dyes (polymethine and oxazine) in the RET-SEARCH (II) reagent penetrate into the
cells and stain DNA/RNA. The stained cells are passed through a semiconductor diode laser
beam and the resulting forward scatter light (cell volume)and fluorescence intensity (RNA
content) are measured. The mature and immature platelet fractions are identified on the basis of
their fluorescence intensity using the XN Software. The IPF is expressed as a proportional value
(IPF%) of the total optical platelet count to indicate the rate of platelet production. Peripheral
blood samples (2 mL) anticoagulated with K2EDTA were analyzed for IPF% and the results
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were recorded. All samples were kept at room temperature until analysis and were analyzed
within8 hr after collection.
Objective 2:
To analyze the impact of thrombocytopenia and of plasma von Willebrand factor (vWf)levels on in-hospital survival in patients with acute on chronic liver failure (ACLF).
Patients with ACLF as per Asia Pacific Association for Study of Liver (APASL) criteria were
enrolled prospectively from October 2014 to March 2015. In patients diagnosed with ACLF after
detailed clinical examination liver function test (LFT), complete blood count (CBC), arterial
blood gas (ABG), creatinine, prothrombin time PT/INR and plasma von Willebrand factor levels
were done (vWf) were done on day of admission. vWf level and the above mentioned
biochemical tests except ABG were repeated on 3rd day of hospital admission. SOFA (sequential
organ failure assessment), MELD (Model for End stage Liver Disease) and CTP (Child-Pugh-
Turcotte) scores were calculated on day of admission.
Presence of sepsis/SIRS (systemic inflammatory response syndrome), and new onset organ
failure (acute kidney injury or hepatic encephalopathy) was documented during hospitalization.
The end point noted was the in-hospital outcomes i.e. discharge, death, discharge in terminal
condition (DTC) or liver transplantation.
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Definitions:
Acute-on-Chronic Liver Failure9:
Patients with ACLF were diagnosed based on APASL criteria i.e. acute hepatic insult
manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or
encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease.
Acute insults: Hepatotropic (HAV/HEV) and non-hepatotropic viruses, reactivation of Hepatitis
B (overt or occult) or Hepatitis C, Other infectious agents afflicting the liver. Alcohol: active
drinking within the last four weeks, use of hepatotoxic drugs, herbs, flare of autoimmune
hepatitis or Wilson’s disease. Surgical intervention and variceal bleed.
Underlying CLD will be diagnosed based on clinical, biochemical, radiological and/or
histological features. Will include compensated cirrhosis of any etiology, Chronic hepatitis,
Nonalcoholic steatohepatitis (NASH), Cholestatic liver disease and  Metabolic liver disease.
Defining the liver failure in ACLF: Jaundice (serum bilirubin ≥5 mg/dL) and coagulopathy
(INR ≥1.5) Ascites and/or encephalopathy as determined by physical examination
Sepsis:
Sepsis is the clinical syndrome that results from a dysregulated inflammatory response to an
infection. Sepsis is defined as the presence (probable or documented) of infection together with
systemic manifestations of infection.
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SIRS (systemic inflammatory response syndrome); SIRS defined as fulfilling at least two of
the following four criteria:
 Fever >38.0°C or hypothermia <36.0°C,
 Tachycardia >90 beats/minute,
 Tachypnea >20 breaths/ minute,
 Leucocytosis >12x109/l or leucopoenia <4x109/l.
Organ Dysfunction: SOFA (sequential organ failure assessment)10Points 1 2 3 4
RespiratoryPaO2/FiO2 <400 <300 <200 <100
With support Without support
CardiovascularHypotension MAP<70mmHg Dopamine <5 Dopamine>5 Dopamine>15
Dobutamine Adr < 0.1 or Adr >0.1 or
NE <0.1 Nor adr >0.1
LiverBilirubin mg/dl 1.2-1.9 2-5.9 6-11.9 >12
RenalCreatinine mg/dl 1.2-1.9 2-3.4 3.5-4.9 5Urine output Or<500ml/d <200ml/day
CoagulationPlatelets x103/µl <150 <100 <50 <25
CNSGCS 13-14 10-12 6-9 <6
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Exclusion criteria
Those with age<18 years and those who didn’t give consent were excluded from study
ACLF grading
Acute-on- chronic liver failure was graded as in EASL-CLIF consortium definition 11
ACLF Grade 0. Comprises of 3 subgroups: first those with no organ failure. Second, those with
single organ failure other than kidney (liver, coagulation, circulation, or respiratory) with serum
Cr level <1.5 mg/dL and no HE. Third, those with single cerebral failure with serum Cr <1.5
mg/dL.
ACLF grade 1. It includes 3 subgroups: first, those with only kidney failure. Second, those with
only liver, coagulation, circulation, or respiratory failure with serum Cr level 1.5-1.9 mg/dL
and/or mild to moderate HE. Third, those with only cerebral failure with serum Cr of 1.5-1.9
mg/dL.
ACLF grade 2. Patients with 2 organ failures are included in this group
ACLF grade 3. Patients with 3 or more organ failures are included under this
Assay for VWF
Plasma VWF antigen (VWF:Ag) was measured using an ELISA kit (quantitiative ELISA) as per
manufacturer’s instructions. In short, diluted plasma was introduced into a microwell coated with
a polyclonal antibody specific for human vWF, which binds to the protein in plasma. Following
a washing step, a polyclonal antibody for vWF coupled to horse radish peroxidase (HRP) was
43
introduced, which binds to free epitopes of immobilized vWF. Following a washing step, the
peroxidase substrate, 3,3',5,5' – Tetramethylbenzidine (TMB), in presence of hydrogen peroxide
(H2O2), was introduced and was observed for blue colour development. When the reaction was
stopped with Sulfuric Acid, a yellow colour was obtained. The amount of colour developed was
directly proportional to the concentration of human vWF in the sample. For VWF collagen
binding (VWF:CB) activity, a similar method using microwells coated with fibrillary collagen
instead of anti-vWF antibody was used. The levels were obtained after analysis of the graphs
shown below.
Graph 1: Standard curve from which the vWf value was calculated
y = -8E-05x2 + 0.027x - 0.000
R² = 0.999
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Statistical methods:
The continuous variables were expressed as mean, median, standard deviation and range. The
discrete variables were expressed as numbers and percentage.
The continuous variables were compared by Mann Whitney U test and a p-value of <0.05 was
considered as significant.
Discrete variables were compared using chi square test or Fischer’s exact test. Bivariate
correlation was assessed by Pearson correlation coefficient.
Multivariate logistic regression was done to assess independent factors affecting survival in
patients with ACLF.
Receiver operating characteristic curve (ROC) was used to assess the sensitivity and specificity
of plasma vWF as predictor of primary outcome.
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Base line characteristics in the study groups
The mean age of the cases was 48 years, in healthy controls it was 32 yrs, 47 years in those with
HBV or HCV related CLD with portal hypertension (disease controls), 29 yrs in those with
EHPVO, 34 years in hematology controls (aplastic anemia or ITP) and 49 yrs in patients with
constitutional macro thrombocytopenia.
Males were predominant among cases (82%), disease controls (84%), EHPVO (69%) and CMT
(80%). It was equal in healthy controls group (50%) and female predominant in hematology
group (53%).
Table 1; Baseline characteristics of different study groups
Characteristics Cases
(n=50)
HBV/HCV
CLD
(n=44)
Healthy
controls
(n=20)
EHPVO
(n=13)
ITP/Aplastic
anemia
(n=39)
CMT
(n=20)
Age
[Median(range)]
44.7(10-
73)
46.6(23-74) 32.3(21-
63)
28.5(13-
55)
33.6(6-69) 48.5(22-
68)
Male: Female 41:9 37:7 10:10 9:4 18:21 16:4
HBV/HCV-Hepatitis B and /or C related cirrhosis with portal hypertension, CMT-Constitutional Macro
Thrombocytopenia, EHPVO-Extrahepatic Portal Vein Obstruction, ITP- Idiopathic Thrombocytopenia
Purpura
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Liver disease severity in the different study groups
In this study three groups with liver disease were included. Cases with cryptogenic CLD
including NCIPH, those with HBV or HCV related CLD with portal hypertension and
extrahepatic portal vein obstruction as controls.
Splenomegaly was noted in majority of patients with portal hypertension and the mean spleen
size in cases was 16.03cm, 14.23cm among those with HBV or HCV related CLD with portal
hypertension and it was 17.35cm, slightly more in comparison to other groups in EHPVO group.
Majority of cases (76%) and extrahepatic portal vein obstruction group were in CTP A class and
in those with HBV or HCV related CLD CTP A class constituted 47% of the total, CTP B and C
constituted 25% and 27% respectively.
Table2: Spleen size and CTP distribution in different liver disease groups
Characteristics Cases (n=50) HBV/HCV (n=44) EHPVO
(n=13)
Spleen size (cm) 16.03(9.2-26.5) 14.23(8.9-21.4) 17.35(13-23.5)
CTP (A:B:C) 38:7:5 21:11:12 12:1:0
EHPVO- extrahepaticportal vein obstruction, HBV/HCV- hepatitis B/ C, Spleen size as per
ultrasound abdomen, CTP- Child-Pugh-Turcott’s score
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Platelet count in the different study groups
When platelet counts were done using two anticoagulants by coulter and manual methods the
difference was noted between manual and coulter platelet counts. This difference was present in
the cases and all the controls groups studied as shown in Table 3.
Table 3: Manual and Coulter platelet counts with different anticoagulants in study groups
Groups EDTA Citrate
Manual
(x103/µL)
Coulter
(x103/µL)
Difference
(x103/ µL)
Manual
(x103/
µL)
Coulter
(x103/
µL)
Difference
(x103/ µL)
Cases (n=50) 82(15-
240)
67(5-179) 15(19-61) 60(8-
163)
47(5-110) 12(27-
138)
HBV/HCV CLD
controls(n=44)
88(16-
194)
76(16-180) 12(22-63) 72(18-
186)
59(4-159) 12(22-72)
Healthy controls
(n=20)
258(124-
348)
239(124-
364)
19(25-64) 208(86-
357)
181(81-
318)
26(40-
108)
EHPVO(n=13) 78(26-
158)
68(14-147) 10(22-33) 64(18-
135)
53(8-117) 10(9-28)
ITP & Aplastic
anemia(n=39)
30(5-165) 24(1-152) 6(28-76) 22(4-
128)
18(2-120) 4(15-79)
CMT(n=20) 125(58-
185)
74(38-97) 52(16-93) ---- --- ----
EHPVO-extrahepatic portal vein obstruction, ITP-idiopathic thrombocytopenic purpura, CMT-
constitutional macrothrombocytopenia, EDTA-ethylenediaminetetraaceticacid
.
48
Mean platelet volume in the study groups
The mean platelet volume was significantly higher in the all the study groups in comparison to
healthy controls both in EDTA and citrate samples. Constitutional macro thrombocytopenia had
significantly higher MPV in comparison to cases (as expected as the cut off for CMT was 13fL).
However the mean platelet volume difference was not significant in cases when compared to
other control groups (HBV/HCV related CLD with portal hypertension, EHPVO and hematology
controls).
Table 4: Mean Platelet Volume in study groups
Cases
(n=50)
HBV/HCV
controls
(n=44)
Healthy
controls
(20)
EHPVO
(n=13)
ITP/Aplastic
anemia
(n=39)
CMT
(n=20)
MPV
EDTA
(fL)
10(7-16) 9.9(7.4-
12.6)
8.7(6.9-
14.2)
10.1(8.3-
12.4)
10(4.8-13.6) 14.1(13-
16.2)
P value* ----- 0.701 0.001 0.424 0.238 <0.001
MPV
Citrate
(fL)
9(7-13) 9.2(6-13) 8.2(6-13) 9(7-13) 9.4(3-15) -----
P value* ----- 0.897 <0.001 0.872 0.931 -----
EHPVO-extrahepatic portal vein obstruction, ITP-idiopathic thrombocytopenic purpura, CMT-
constitutional macrothrombocytopenia, MPV-mean platelet volume, *All p values as compared to cases
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Corrected difference in platelet count in the study groups
In EDTA sample, in different groups
Platelet count difference was corrected for the total platelet counts as different study groups had
different numbers and the total count may affect the difference. The mean corrected difference in
platelet count-EDTA (CDPC=manual platelet count-coulter platelet count/coulter platelet count)
in cases [0.331(-0.22-2.0)] was significantly different in comparison to healthy controls [0.091(-
0.13-0.52); P 0.002]. However, it was (? Not) significantly different in citrate sample [0.492(-
0.50-11.5); 0.173(-0.18-0.93); P 0.330].
Table 5; Corrected difference in platelet count in different study groups with EDTA
sample
Groups CDPC –EDTA P value
Cases 0.331(-0.22-2.0)
HBV/HCV controls 0.282(-0.20-1.94) 0.290
Healthy controls 0.091(-0.13-0.52) 0.002
EHPVO 0.258(-0.15-0.86) 0.519
ITP & Aplastic anemia 1.247(-0.45-19) 0.383
CMT 0.701(0.19-1.02) 0.000
CDPC-corrected difference in platelet count, EHPVO-extrahepatic portal vein obstruction, ITP-idiopathic
thrombocytopenic purpura, CMT-constitutional macrothrombocytopenia
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Graph 1: Graph depicting the difference in corrected platelet counts in different study groups
with EDTA as anticoagulant
*Hemat- Aplastic anemia & ITP
In Citrate samples, in different groups
Mean CDPC –citrate was significantly different in hematology controls [0.988(-0.44-7.18)] in
comparison to cases [0.492(-0.50-11.5); P 0.010]. But, in EDTA sample the difference was not
significant [1.247(-0.45-19); 0.331(-0.22-2.0); P 0.383].
The mean CDPC-EDTA was significantly higher in patients with constitutional macro
thrombocytopenia [0.701(0.19-1.02)] in comparison to cases [0.331(-0.22-2.0); P 0.000]
51
Table 6: Corrected platelet count in different groups in citrated sample
Groups CDPC-Citrate P value
Cases 0.492(-0.50-11.5) ----
HBV/HCV controls 0.372(-0.40-4.0) 0.562
Healthy controls 0.173(-0.18-0.93) 0.330
EHPVO 0.334(-0.29-1.25) 0.604
ITP & Aplastic anemia 0.988(-0.44-7.18) 0.010
CMT --- ----
CDPC-corrected difference in platelet count, EHPVO-extrahepatic portal vein obstruction, ITP-idiopathic
thrombocytopenic purpura, CMT-constitutional macrothrombocytopenia
Graph 2: Graph depicting the difference in corrected platelet counts in different study groups
with citrate as anticoagulant
Hemat- Aplastic anemia & ITP
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Platelet clumping
Platelet clumping was noted in 9(18%) cases, 5(11.4%) HBV/HCV CLD controls, 2(10%)
healthy controls and 3 (15%) constitutional macrothrombocytopenia patients in the peripheral
smear. In patients with EHPVO, aplastic anemia and ITP clumping was not noted in the
peripheral smear.
There was no difference noted in the platelet clumping in EDTA and citrate samples. Both the
anticoagulants had similar clumping profile.
Table 7: Platelet clumping in study groups
Cases
(n=50)
HBV/HCV
controls
(n=44)
Healthy
controls
(n=20)
EHPVO
(n=13)
ITP &
Aplastic
anemia
(n=39)
CMT
(n=20)
Platelet
clumps-
EDTA
n(%)
9 (18) 5 (11.4) 2 (10) 0 (0) 0 (0) 3 (15)
----- 0.400 0.500 0.200 0.004 1.00
Platelet
clumps
Citrate
n(%)
9 (18) 5 (11.4) 2 (10) 0 (0) 0 (0) 3 (15)
---- 0.400 0.500 0.200 0.004 1.00
EHPVO-extrahepatic portal vein obstruction, ITP-idiopathic thrombocytopenic purpura, CMT-
constitutional macrothrombocytopenia
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Graph 3: Graph depicting the platelet clumping in different study groups
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Immature platelet fraction in study groups
We studied immature platelet fraction in 23 cases (cryptogenic cirrhosis with portal
hypertension including NCIPH), 14 disease controls (HBV/HCV related chronic liver disease
with portal hypertension), 19 healthy controls, 2 patients with aplastic anemia and ITP each.
The mean age in the cases was 46.6 (24-81) years; it was (51.534-64) yrs in disease controls,
31.2 (23-42) years in healthy controls, 32(23-41) yrs in aplastic anemia group and 32.5 (23-42)
years in those with ITP.
Male and female were almost equal in number in cases and healthy controls (11:2, 10:9; M:F).
Disease control group was female predominant (10:4). In hematology patients aplastic anemia
patients were males and ITP were females.
The mean platelet count and mean platelet volume was low among the study groups except in
healthy controls. Patients with HBV/HCV related chronic liver disease patients had lower
platelet count compared to cases.
Mean spleen size was more in both the liver disease groups, it was more so in cases in
comparison to HBV/HCV CLD controls.
Immature platelet fraction was elevated in liver disease group and ITP patients. Those with
HBV/HCV CLD group (7.8) had higher IPF compared to cryptogenic CLD group (6.3). IPF was
significantly higher in both the patients of ITP and was with in lower range in aplastic anemia
group. Healthy controls had mean IPF of 3.1
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Table 8: Platelet count, mean platelet volume, immature platelet fraction, spleen size and
CTP in the study groups
Characteristics Cryptogenic
chronic liver
disease(n=23)
HBV/HCV-
chronic liver
disease(n=14)
Healthy
controls(19)
Aplastic
anemia(n=2)
ITP(n=2)
Platelet
count(x103/µL)
142.7(20-698) 84.21(15-143) 322(219-426) 28.5(5-52) 43(14-72)
Mean platelet
volume(fL)
11.9(10-14) 12.92(10-14) 10.38(9-12) 12.25(11-14) 14(14-14)
IPF (%) 6.3(1.2-28.3) 7.8(2.9-17.3) 3.1(0.8-6.1) 2.2(2.2-2.3) 19.3(13.4-
25.2)
Spleen size
(cm)
16.5(10-26) 13.6(10-20) ---- ---- ----
CTP (A:B:C) 11:7:5 3:4:7 ----- ---- ----
IPF-immature platelet fraction, HBV/HCV- hepatitis B and hepatitis C, ITP-idiopathic thrombocytopenic
purpura, CTP- child pugh turcot’s
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Comparison of platelet factors in different groups
Comparison between cryptogenic and HBV/HCV chronic liver disease
When the platelet count, mean platelet volume, spleen size and IPF was compared in cryptogenic
chronic liver disease group with those with HB/HCV chronic liver disease group the difference
in MPV and spleen size was significantly different. However, the difference in platelet count and
IPF was not statistically significant
Comparison between cryptogenic chronic liver disease and healthy controls
When mean platelet count, mean platelet volume and immature platelet fraction was compared
between cryptogenic chronic liver disease and healthy controls the difference in all the three
groups were statistically significant. Platelet count was significantly low, mean platelet volume
was higher and IPF was higher in cryptogenic CLD group compared to healthy controls
Table 9: Comparison of platelet count, mean platelet volume and immature platelet
fraction among cryptogenic chronic liver disease and healthy controls and HBV/HCV
controls
Cryptogenic
chronic liver
disease(n=23)
Healthy
controls(n=19)
HBV/HCV-
chronic liver
disease(n=14)
P value
cases/healthy
controls
P value
Cases Vs
HBV/HCV
controls
Platelet
count
(x103/µL)
142.7(20-698) 322(219-426) 84.21(15-143) 0.000 0.394
MPV(fL) 11.9(10-14) 10.38(9-12) 12.92(10-14) 0.001 0.042
IPF (%) 6.3(1.2-28.3) 3.1(0.8-6.1) 7.8(2.9-17.3) 0.002 0.284
Spleen
size (cm)
16.5 (10-26) ------ 13.6(10-20) ----- 0.039
IPF-immature platelet fraction, HBV/HCV- hepatitis B and hepatitis C
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Graph 4: Immature platelet fraction in different study groups
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Correlation between IPF and mean platelet volume
When linear correlation between MPV and IPF was analyzed using Pearson’s correlation
coefficient, a statistically significant (P 0.000) strong correlation (r 0.718) was found between
mean platelet volume and immature platelet fraction.
In chronic liver disease group
When the correlation was separately analyzed for those with liver disease (cryptogenic CLD and
HBV/HCV CLD) with healthy controls there was statistically significant(P 0.000) good
correlation (r 0.642)between MPV and IPF.
Graph 5: Correlation between mean platelet volume and immature platelet fraction in liver
disease
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In healthy controls
There was a strong (r 0.894) and statistically significant (p <0.001) correlation between mean
platelet volume and immature platelet fraction in healthy controls
Graph 6: Correlation between mean platelet volume and immature platelet fraction in
healthy control group
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Correlation matrix
In the study group as a whole
When correlation was analyzed in relation to IPF, MPV, spleen size and platelet count in the
study group a statistically significant good positive correlation was noted between IPF and MPV.
A statistically significant good negative correlation was noted between MPV, IPF and platelet
count. This correlation has been depicted in above graph
Table 10: Correlation matrix between platelet counts, mean platelet volume, immature
platelet fraction and spleen size in study group
IPF % MPV (fl) Spleen size
(cm)
Platelet count
(x103/µL)
IPF % Pearson CC
P value
1 0.640
0.000
0.015
0.933
-0.394
0.002
MPV(fl) Pearson CC
P value
0.646
0.000
1 0.279
0.104
-0.632
0.000
Spleen
size(cm)
Pearson CC
P value
0.015
0.933
0.279
0.104
1 -0.193
0.268
Platelet
count
(x103/µL)
Pearson CC
P value
-0.394
0.002
-0.632
0.000
-0.193
0.268
1
IPF-immature platelet fraction, MPV-mean platelet volume, Pearson CC- Pearson correlation coefficient
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Graph 7: Correlation matrix of platelet counts, mean platelet volume, immature platelet
fraction and spleen size in study group
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Correlation matrix in liver disease
When the correlation was analyzed in the liver disease group a statistically significant positive
correlation was noted between immature platelet fraction and mean platelet volume. A
Statistically significant negative correlation between platelet count and mean platelet volume
was also noted
Table 10: Correlation matrix between mean platelet volume, immature platelet fraction ,
spleen size and platelet count in liver disease group (cryptogenic, HBV and HCV- chronic
liver disease)
IPF % MPV (fl) Spleen size
(cm)
Platelet count
(x103/µL)
IPF % Pearson CC
P value
1 0.573
0.000
0.018
0.919
-0.170
0.315
MPV(fl) Pearson CC
P value
0.573
0.000
1 0.244
0.164
-0.356
0.031
Spleen
size(cm)
Pearson CC
P value
-0.018
0.919
0.244
0.164
1 -0.223
0.206
Platelet count
(x103/µL)
Pearson CC
P value
-0.170
0.135
-0.356
0.031
-0.223
0.206
1
IPF-immature platelet fraction, MPV-mean platelet volume, Pearson CC- Pearson correlation coefficient
.
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Graph 8: Correlation matrix of mean platelet volume, immature platelet fraction , spleen
size and platelet count in liver disease group (cryptogenic, HBV and HCV- chronic liver
disease)
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Correlation matrix in healthy controls
When correlation was analyzed between immature platelet fraction, mean platelet volume and
platelet count in healthy controls a statistically significant good positive correlation was noted
between immature platelet fraction and MPV and a statistically significant good negative
correlation was noted between platelet count and immature platelet fraction, so also platelet
count and mean platelet volume.
Table 12: Correlation matrix between mean platelet volume, immature platelet fraction,
and platelet count in healthy control group
IPF % MPV (fl) Platelet count
(x103/µL)
IPF % Pearson CC
P value
1 0.840
0.000
-0.722
0.000
MPV(fl) Pearson CC
P value
0.840
0.000
1 -0.735
0.000
Platelet count
(x103/µL)
Pearson CC
P value
-0.722
0.000
-0.735
0.000
1
IPF-immature platelet fraction, MPV-mean platelet volume, Pearson CC- Pearson correlation
coefficient
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Graph 9: Correlation matrix of mean platelet volume, immature platelet fraction, and
platelet count in healthy control group
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Results of Objective 2:
Characteristics in patients with Acute-on-Chronic Liver Failure group
We recruited 50 patients with ACLF as per APASL criteria for the study. The mean age in the
study group was 43.5 years. Males predominated the study (90%), ethanol was the most common
cause (80%) in the study followed by cryptogenic liver disease and hepatitis B.
Table 13: Characteristics in patients with Acute-on-Chronic Liver Failure group
Characteristics Median (Range)- n=50
Age (years) 43.5 (28-64)
Male: Female 45:5
Etiology
Ethanol
HBV/HCV
Cryptogenic
Others
40(80%)
4(8%)
5(10%)
1(2%)
Severity of liver disease in ACLF
Mean MELD score in the study group was 30 and SOFA 7.6 indicating the severity with which
they presented. 16 (32%) patients did not have any major organ injury in this study and
constituted ACLF grade 0, 13 (26%) each in ACLF grade 1 and 2 and 8 (16%) had 3 organ
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injury constituting ACLF grade 3. 41 (82%) of patients with ACLF had features of SIRS at
admission
Duration and outcome of hospital stay: Among 50 patients, 29 got discharged, average
hospital stay was 8.2 (3-28)days, 10 died, average hospital stay was 6.5 (2-12) days, 9 were
discharged in terminal condition, average hospital stay was 5.7 (2-11) days and 2 underwent liver
transplantation, average number of hospital stay prior to LTx was 8 (5-11) days.
Table 14: Severity of liver disease in patients with acute-on-chronic liver failure
MELD 30 (17-49)
SOFA- Day 1 7.62(4-14)
ACLF grading
(Grade 1:2:3)
16:13:13:8
Bilirubin (mg/dl) 17.3 (5-37)
SIRS n(%) 41/50 (82)
INR 2.3 (1.5-10)
Albumin (g/dl) 2.35 (1.5-3.4)
Platelet count (x103/µL) 110 (30-243)
Hospital stay (no. of days) 7.3 (2-28)
68
Plasma von Willebrand factor antigen and activity levels
In patients with ACLF the mean plasma vWf Ag level on day 1 was 756 and on day 3 it was 712.
vWf activity on day 1 was 570 and on day 3 it was 562 as shown in Table 15.
Table 15: Plasma von Willebrand antigen and von Willebrand factor activity in patients
with acute on chronic liver failure on day 1 and day 3
Parameters Median (Range)
vWf Ag day 1 % (n=46) 756 (212-1346)day 3 % (n=42) 712 (278-1411)
vWf activity day 1% () 570 (97.3-1156)
day 3 562 (100-1300)
Difference in patient characteristics in relation to in hospital outcome
MELD was significantly different in those who did not survive compared to those who survived.
Mean MELD in those who died was 33.9 and 27.2 in those who got discharged. SOFA score and
bilirubin on day of admission was also significantly different.
Higher number of patients in group 1 (composite poor in-hospital outcome-death/DAMA/LTx)
had high creatinine compared to group 2 (discharge). There was no significant difference in
SIRS, lactate, platelet count and albumin in both the groups. vWf activity on day 1 was
significantly different in group 1 compared to group 2. vWf Ag D1, D3 and vWf activity on D3
was almost similar in both the groups.
On multivariate logistic regression analysis controlling for MELD score vWf activity at
admission (p 0.102) had a trend towards prediction of mortality [AOR 1.002; 95%CI (1-1.005)]
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Table 16: Difference in base line characteristics in those who survived and those who did
not
Characteristics Composite poor
outcome (n=21)
Discharged in stable
condition (n=29)
P value
Age (years) 40 (30-58) 43 (28-64) 0.687
MELD 35 (22-47) 26 (17-49) 0.002
SOFA score 8 (4-14) 6 (4-14) 0.007
Bilirubin (mg/dl) 21.7 (5.1-37) 11.6 (5-33.4) 0.013
Albumin (gm/dl) 2.3 (1.8-3.3) 2.3 (1.5-3.4) 0.760
INR 2.17(1.5-10) 1.9 (1.5-3.4) 0.293
Platelet count (x103/ µL) 96(30-353) 92(30-240) 0.969
Creatinine 2.2 (1-6) 1 (1-6) 0.005
Lactate 1.9 (1-7) 1.5(1-16) 0.113
SIRS 17/21 24/29 1.000
vWf Ag day 1 742(264-1347) 699 (212-1249) 0.135
vWf Ag day 3 746(326-1157) 689 (279-1411) 0.600
vWf activity day 1 632 (119-1157) 490 (97-986) 0.025
vWf activity day 3 457(244-1334) 497 (100-1304) 0.916
ACLF grades and relation to in-hospital outcome
When the data was analyzed as per the grade of ACLF, MELD was significantly different in
different grades. As the grade of ACLF increased MELD also increased.
vWf activity was also significantly increasing as the grade of ACLF increased from grade 0 to 3.
In-hospital mortality also significantly increased with increasing grade.
However vWf Ag on D1 and 3, vWf activity on D3 was not significantly different in different
grades.
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Table 17: ACLF grades and its relation to in-hospital outcome
ACLF grades P
valueGrade 0 (n=16) Grade 1(n=13) Grade 2 (n=13) Grade 3 (n=8)
Age( years) 41 (30-63) 49 (30-62) 41 (28-64) 40.5 (35-58) 1.140
MELD 23 (19-27) 29 (17-36) 37 (26-47) 41 (30-49) <0.001
vWf Ag D1 % 690 (264-1082) 700 (212-1347) 686 (515-1338) 986 (742-1344) 0.107
vWf Ag D3 % 654 (301-1169) 640 (279-1411) 594 (334-998) 885 (702-1054) 0.184
vWf activity D1 % 491 (97-949) 468 (116-835) 532 (221-1090) 882 (676-11157) 0.005
vWf activity D3 % 466 (100-1247) 447 (132-1218) 441 (277-1304) 766 (713-904) 0.081
Platelet (x103/µL) 99 (39-243) 71 (30-225) 121 (30-353) 94 (35-198) 0.549
In hospital outcome
Death (%)
1(6) 5 (38.5) 10 (76.9) 5 (62.5) <0.001
Graph 10: Depiction of vWf Ag on day 1 in different study group
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Graph 11: Depiction of vWf activity on day 1 in different study group
ROC for MELD, vWF Ag and vWf activity
ROC was plotted for MELD, vWf Ag on day1 and vWF activity on D1. The sensitivity and
specificity for different cut off are given in the table below.
AUROC for MELD was 0.744 (95% CI; 0.599-0.888), AUROC for vWf Ag D1 was 0.631 (95%
CI; 0.465-0.796) and AUROC for vWf activity D1 was 0.681 (95% CI; 0.521-0.842).
A MELD cut off of 28 had 74% sensitivity and 63% specificity, vWf Ag cut off of  529 had 84%
sensitivity and 33% specificity and vWf activity cut off of 402 had 79% sensitivity and
33%specificity.
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Graph 12; Receiver Operating Characteristic curve for MELD, vWf Ag and vWf acticity at
admission to predict survival
Area P value 95% confidence interval
Lower bound Upper bound
MELD 0.744 0.005 0.599 0.888
vWf Ag D1 0.631 0.138 0.465 0.796
vWf Activity D1 0.681 0.038 0.521 0.842
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Table 18: Area under receiver operating curve for vWf Ag and vWf activity on Day 1 of
admission in acute-on-chronic liver failure patients
Cut-off value Sensitivity (%) Specificity (%)
MELD
22 100 26
26 90 48
28 74 63
31 63 78
vWf Ag D1
492 95 22
529 84 33
685 74 48
865 42 70
vWf Activity D1
291 90 26
402 79 33
507 74 56
621 53 63
Correlation matrix for MELD, vWf Ag, vWf activity and platelet count
On correlation matrix analysis a significant strong positive correlation was noted between vWf
Ag and activity.
A significant weak positive correlation was noted between MELD and vWf activity D1.
A weak negative correlation was noted between vWf Ag and vWf activity with platelet count.
However, it was not statistically significant.
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Table 19: Correlation matrix for MELD, von Willebrand factor antigen, von Willebrand
factor activity and platelet count
MELD vWf Ag D1 vWf activity
D1
Platelet
count
MELD Pearson CC
P
1 0.249
0.095
0.321
0.023
0.031
0.832
vWf Ag D1 Pearson CC
P
0.249
0.095
1 0.831
<0.001
-0.136
0.372
vWf activity
D1
Pearson CC
P
0.321
0.023
0.831
<0.001
1 -0.165
0.253
Platelet
count
Pearson CC
P
0.031
0.832
-0.135
0.372
-0.165
0.253
1
Pearson CC- Pearson correlation coefficient
Graph 13; Correlation matrix for MELD, von Wilebrand factor antigen, von Willebrand
factor activity and platelet count
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This was a prospective observational study done to analyze platelet clumping in patients with
portal hypertension. Various control groups as mentioned in methodology were included to
compare the results with cases (cryptogenic cirrhosis with portal hypertension including non-
cirrhotic intrahepatic portal hypertension).
In our study difference between manual and coulter platelet count was noted in the study groups
along with those with liver disease. This difference was significant in cases when compared to
healthy controls. This difference is most probably due to increased mean platelet volume which
was significantly higher in cases compared to healthy controls and the MPV was significantly
correlating with immature platelet fraction indicating increased large immature platelets in the
circulation. In our study one of the reasons for increased immature platelets in the circulation
secondary to increased peripheral destruction/ sequestration in the setting of liver disease was
studied. vWf Ag and activity was increased in patients with ACLF and a negative correlation
was also noted between vWf activity and platelet count suggesting role of vWf in peripheral
platelet destruction/sequestration.
We observed difference between manual and automated coulter platelet count in all the groups
including healthy controls and the difference was significantly different in cases (cryptogenic
cirrhosis with portal hypertension including non-cirrhotic Intrahepatic portal hypertension) in
comparison to healthy controls  in EDTA sample but not in citrate sample. Similar significant
difference was noted when compared with citrated sample in hematology controls (aplastic
anemia and ITP), so also in comparison to constitutional macrothrombocytopenia.
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The difference noted in CMT group was significantly higher in comparison to cases. The
differences noted are specifically seen in either EDTA or citrate and the results are not consistent
with different anticoagulants in same group. This may point towards anticoagulant related
spurious platelet count results.
In a study by M Zandecki et al1 it was concluded that EDTA dependent thrombocytopenia is one
of the frequent anomalies associated with spurious counts on automated counters. It was
attributed to platelet clump formation due to EDTA. However in our study this anomaly is
unlikely as the study was designed to avoid this and there was no increased clumping noted in
EDTA samples compared to citrate samples.
Anton H. Sutor et al2 has shown in their study that automated counter can’t be relied up on in
cases of thrombocytopenia especially if count was lower than 20000 as the average difference in
automated and manual count was 7000/ µL, which in our study was not common. Cases and all
the control groups except the hematology controls had mean platelet count >50,000/µL.
However other causes for spurious low platelet count in automated platelet counts like platelet
satellitism, platelet-neutrophil agglutination, fragmented RBC’s, cytoplasmic fragments,
cryoglobulins, bacteria and coagulation within sample listed by M Zandecki et al1 were not
looked into in our study.
One more important cause of spurious low platelet count in automated platelet count is abnormal
platelet size. In our study the mean platelet volume was measured in all cases and control groups
and was noted that, MPV in cases was significantly higher in comparison to healthy controls.
This difference in mean platelet volume may explain the difference in platelet count noted
between manual and coulter platelet counts.
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Increased mean platelet volume was noted in all the study groups in comparison to healthy
controls so also the difference in corrected platelet counts. Hence increased MPV is the likely
explanation for the difference in manual and coulter platelet count.
Our hypothesis to start with was that, the difference in manual and coulter platelet count is due to
platelet clumping and this platelet clump leads to portal venular occlusion leading to obliterative
portal venopathy. However we did not find platelet clumping in the peripheral circulation which
was significantly different from other study groups and the difference in platelet count was noted
in other study groups also.
Platelet clumps in peripheral circulation was noted in 18% of cases, 11.4% HBV/HCV related
portal hypertension, 15% CMT patients and 10% of healthy controls also. So, platelet clumping
may not be the cause of this difference as hypothesized. However platelet clumping at
microvascular level as cause of oblitrative portal venopathy cannot be ruled out with this study.
Increased mean platelet volume may be due to immature platelets in the circulation or due to
activated platelets in the circulation. To understand this better we did immature platelet fraction
estimation in patients with liver disease and compared with healthy controls.
Further, when the difference in manual and coulter platelet count was noted in all the study
groups along with increased mean platelet volume when compared to healthy individuals it was
suggesting that the difference noted was most probably due to increased platelet volume.
Increased platelet volume means either activated platelets or immature platelets. Immature
platelets are released into peripheral circulation when there is high turnover due to increased
peripheral destruction.
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In our study those patients with HBV/HCV related chronic liver disease with portal hypertension
had lower platelet count compared to cryptogenic chronic liver disease with portal hypertension.
This can be explained with the higher number of CTP C patients in the former group which
reflects more severe liver disease.
Studies 3,4 have shown that immature platelet fraction measurement based on flowcytometry
principle using fluorescent dye is a good test to measure the immature platelet fraction in the
peripheral circulation. So, we did IPF measurement in total 60 patients.
In a study by Sehgal K et al5 it was found that the normal IPF% in healthy individuals was 0.7-
4.3%. In another study of Carlos Brigg’s et al3 in western healthy population the IPF% varied
from 1.1-6.1%. Carlos Brigg’s et al studied IPF% in different study groups and they found that in
patients with ITP IPF varied from 2.3-52.1% and in TTP it varied from 11.2-30.9%.
In our study the IPF% varied from 0.8-6.1% in healthy individuals and was in line with the
above mentioned studies. Similarly in aplastic anemia and ITP patients also the results were in
line with the other studies. ITP patients had significantly higher IPF% as they have normal bone
marrow production with peripheral destruction. Whereas in aplastic anemia as bone marrow
production is abnormal as expected IPF% was low.
In a study by T Nomura et al6 it was noted that patients with liver disease have higher IPF
fraction compared to healthy controls [5.4(3-9.5); 3(0.7-7.3)]. Similarly in a study by Issac Pons
et al7 it was shown that patients with liver cirrhosis (HCV/HBV and cryptogenic cirrhosis) with
splenomegaly had significantly high IPF% compared to healthy controls.
In our study we noted that patients with portal hypertension had higher IPF% compared to
healthy controls. When cryptogenic chronic liver disease with portal hypertension group was
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compared with healthy controls IPF% was significantly higher in the cryptogenic chronic liver
disease group (p 002).
In our study a significant strong (p <0.001, r 0.718) linear correlation was noted between mean
platelet volume and immature platelet fraction. As expected, thrombocytopenic patients had
higher MPV and IPF in the circulation suggesting that mean platelet volume can be considered
as an indirect measure of immature platelets.
Further on analysis a statistically significant strong negative correlation was found between
platelet count and immature platelet fraction when cryptogenic chronic liver disease with portal
hypertension patients were compared with healthy controls (p <0.001; r 0.722). This suggested
increased peripheral destruction of the platelets in patients with portal hypertension. This finding
supports the fact that in liver disease hypersplenism is an important cause of thrombocytopenia.
This finding suggests that the bone marrow function is normal in patients with chronic liver
disease with portal hypertension as against some studies which suggested suppressed bone
marrow function as a cause of thrombocytopenia in chronic liver disease with portal
hypertension. However, when the correlation between spleen size and IPF and platelet count was
analyzed, no significant correlation was noted which may be because the spleen size
measurement in ultrasound abdomen may not be the accurate measurement of actual spleen size
and also it is known fact that hypersplenism is not related to spleen size8.
In our study it was also noted that there was significant strong negative correlation between
platelet count and mean platelet volume in patients with cryptogenic chronic liver disease with
portal hypertension when compared to healthy controls. This finding is in line with findings in
first group of our study as described above. This negative correlation is mostly because the
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automated platelet count is lower when the MPV increases as the impedance technique may miss
giant platelets while counting.
To explore the cause of peripheral platelet destruction/sequestration we studied vWf in patients
with ACLF. In our study increased vWf Ag and activity was noted in those who had poor in-
hospital outcome. There was significant increase in vWf activity with increasing grades of ACLF
and a negative correlation of vWf activity with platelet count.
In CANONIC study11, a study in the western population the mean age in ACLF patients was
56±11 years and was male predominant (64.4%). In a study by Khot A A et al9 from Mumbai the
mean age was 43.1 years and was predominantly males (54%). In another study from Jaipur10 the
mean age was 38.6±16.7 years and was also male predominant (78.8%). Garg H et al11 studied
hemodynamics in 57 patients with ACLF and the mean age group in the study patients was 41
(15-67) yrs. Swastik A et al12 from Chandigarh studied 106 patients with ACLF and the mean
age was 45±11 years with male predominance (87%). In our study the mean age in the study
group was 43.5 (28-64) years and was predominantly males (90%). ACLF affects relatively
younger age group as shown in above mentioned studies. More so in the Asian countries as the
main cause in the Asian countries is viral or alcoholic.
In ACLF study by Moreau R et al11 the main cause of underlying cause of cirrhosis was alcohol
(49.2%) followed by chronic hepatitis C (21.4%), most common acute insult was sepsis (21.4%)
followed by variceal bleed (17.3%). In a study from New Delhi by Garg V et al13 the most
common cause of cirrhosis was ethanol (74%) followed by hepatitis B (17%) and cryptogenic
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(9%). So also the common acute insult alcohol (65%) followed by hepatitis B flare (17%) and
anti tubercular drugs (9%). In a study from Jaipur by AK Jha et al10 the most common cause of
cirrhosis was cryptogenic (30.7%) followed by ethanol (28.8%) and hepatitis B (19.3%). In
another study from Mumbai by A A Khot et al9 the most common cause of underlying CLD was
hepatitis B (29.6%) followed by cryptogenic (27.7%) and ALD (14.8%). Most common acute
insult in this study was acute hepatitis followed by sepsis. One more study by Swastik A et al12
from PGI Chandigarh has shown alcohol as most common cause of CLD (66%) followed by
cryptogenic CLD (11%) and hepatitis B related CLD (8%)
In our study the most common cause of underlying CLD was alcoholic liver disease (80%)
followed by cryptogenic CLD (10%) and hepatitis B (8%). This finding is in line with studies
from western countries and Indian studies, Garg V et al13. and Swastik A et al12. However the
etiological profile has been different from other studies mentioned above.
The mean MELD score in the study subjects in CANONIC study11 was 18.8±7.5 and 75.7% of
the patients had Grade 0 ACLF, 13.7% grade1, 7.4% grade 2 and 3.2% grade 3 ACLF. In a study
by Swastik et al12 from PGI Chandigarh the MELD score was 33±9 and the SOFA score was 8
(3-20). When the patients in this study were classified as per ACLF grades Grade 0 had 19.8%%,
Grade 1 had 25.5%, grade 2 had 22.6% and grade 3 had 32% of patients. In study by Garg V et
al13 from Delhi the MELD score was 29 (21-40) and SOFA score was 5 (4-9).
In our study the mean MELD score was 30 (17-49) and SOFA score was 7.6 (4-14). These
findings were in line with the above mentioned Indian studies from different centers, however, in
comparison to CANONIC study MELD score was significantly higher in all these Indian studies
including ours. This suggests more severe disease at presentation in our study population. When
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our study population was divided based on ACLF grades as in CANONIC study grade 0 had
32%, grade 1 and 2 had 26% each and grade 3 had 16% of patients. This finding contradicts the
results from the above mentioned Indian study where grade 3 had highest number of patients and
that of CANONIC study which had highest number in grade 0 ACLF. Our study had only 50
patients where as in other studies numbers of patients were much higher. The difference in
results we got may be because of the small study population or because of the referral bias, in
our study and one from Chandigarh as both are tertiary referral hospitals we may be getting more
sick patients.
In Swastik A et al12 study the overall in hospital mortality was 48% and when divided according
to ACLF grades grade 0 had 9.5%, grade1 had 29.6%, grade 2 had 58.3% and grade 3 had 79.4%
mortality. In Moreau R et al11 study no in hospital data was available but 28 and 90 day mortality
was correlating with the grades of ACLF, higher the grade more the mortality was. In A K Jha et
al10 study from Jaipur the in-hospital mortality was 61.4% and the mean number of days of
hospital stay was 4.9 days. In a study from Mumbai by A A Khot et al9 in-hospital mortality was
62.9%.
In our study in-hospital mortality was 42% and mean number of days of hospital stay was 7.3
days. This finding is in line with study from Chandigarh which had a comparable study
population. However it contradicts other Indian study data, it may be because of difference in the
study population.
Further when our study group in-hospital mortality was subdivided as per the ACLF grading
grade 0 had 6%, grade 1 38.5%, grade 2 76.9% and grade 3 had 62.5% mortality. This finding
was almost in line with above mentioned study by Swastik et al12 except for difference in grade 2
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and 3 mortality rates. Grade 3 had lower mortality rates in contradiction to expected higher
mortality.
The mean platelet count in CANONIC study11 was 100x109/L and when it was compared with
those who did not have ACLF it was significantly different (110x109/L; p 0.02), further when it
was analyzed in relation to grades of ACLF, platelet count significantly decreased with
increasing ACLF grade. In Swastik et al12 study the mean platelet count was
99.5x103/mm3.There was no data available in this study regarding platelet count in different
grades of ACLF. In our study the mean platelet count was 110x103/µL. and when it was
analyzed in relation to different grades of ACLF there was no significant difference noted. Even
when it was compared with those who survived and those who did not there was not much
difference in platelet count.
The finding of CANONIC study11 support the hypothesis that increased vWf in ACLF leads to
thrombus formation in the microcirculation leading to TMA which in peripheral circulation will
be reflected as thrombocytopenia when analyzed in terms of platelet count alone as
thrombocytopenia increases with increase in number of organ failure, however vWf was not
measured in that study and this study had good large study population in its favor which we lack.
If patients with ACLF develops TMA as hypothesized will consume platelets as in TTP and as
number of platelets is the primary drive for the bone marrow to sense and produce platelets, this
increased consumption of platelets at the microcirculatory level can stimulate bone marrow and
produce more platelets as a compensatory response which can explain relatively normal platelet
count.
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To best of our knowledge this is the first study of vWf in ACLF patients. vWf ADAMTS 13
imbalance has been studied in liver cirrhosis, alcoholic hepatitis, sepsis and acute liver failure
setting but not in ACLF.
In a study by J A Kremer Hovinga et al14 from Switzerland ADAMTS 13 and vWf Ag and
activity was studied in patients with severe sepsis and septic shock. It was found that those with
sepsis had significantly higher levels of vWF (373 Vs 89; p <0.001), vWf activity (344 Vs 118; p
<0.001) and low ADAMTS 13 levels (60 Vs 110; p <0.001) in comparison to healthy controls.
In another study by J J J Hulstein et al15 from Netherlands small number of preeclampsia and
HELLP syndrome along with healthy pregnant women were studied. They found that patients
those with HELLP had significantly low platelet count in comparison to preeclampsia patients
(70 Vs 251 x103/µL). When vWf level was measured those with preeclampsia had significantly
higher level in comparison to healthy pregnant women but was not significantly different from
those with HELLP. But, vWf activity was significantly higher in those with HELLP compared to
healthy and preeclampsia women. The author’s concluded acute activation of the endothelial cell
layer in HELLP syndrome results in increased vWf antigen and vWf pro-peptide levels.
In a study by Ton Lisman et al16 from Netherlands it was shown that vWf level was significantly
elevated in patients with cirrhosis along with significantly decreased ADAMTS13 levels and
further they showed that adhesion of either normal or patient platelets to a collagen surface was
substantially increased when these platelets were resuspended in plasma of patients with
cirrhosis, as compared with control plasma. The authors of this study concluded that highly
elevated levels of VWF in patients with cirrhosis contribute to the induction of primary
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hemostasis despite reduced functional properties of the molecule. This phenomenon might
compensate for defects in platelet number and function in patients with cirrhosis.
In our study both vWf Ag and vWf activity (collagen binding assay) was measured. And it was
found that in patients with ACLF both vWf Ag and vWf activity was significantly elevated and
vWf activity at admission was significantly higher in those who did not survive when compared
those who did well and was discharged in stable condition. This significant difference was
preserved even when it was analyzed in terms of ACLF grades. As the grade of ACLF increased
vWf activity also increased suggesting its role in organ dysfunction.
.
When the level of vWf Ag and activity was repeated on day 3 in our study there was no
significant difference. In a study by R A Reiter et al17 from Vienna it was demonstrated that in
healthy individuals when endotoxin was injected inflammation was induced and the vWf  Ag
level was elevated significantly which got normalized only by day 7. They had checked the
levels on day 3 but it remained elevated then.
In our study no significant difference was noted in day 1 and day 3 vWf Ag or activity levels.
and was not predicting in-hospital survival
The vWf Ag, activity and ADAMTS13 levels along with platelet levels in different studies with
variable population and disease settings in the background of liver disease and inflammation has
been listed in the below table
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Table 1: Different studies in various liver diseases in relation to vWf
Study Cases (n)
Controls (n)
vWf
Ag%
vWf
activity%
ADAMTS13% Platelet
count
JJJ Hulstein et al15 HELLP
syndrome (14)
339 253 ---------- 70
Healthy (9) 272 151 251
M Ferlitsch et al12 Compensated
CLD (145)
394 ---------- ---------- -----------
Decompensated
CLD (141)
264
Greg C. G.
Hugenholtz et al 18
ALF (50) 547 97 28
Healthy (40) 107 105 92
Ashish G et al4 Cryptogenic
CLD (22)
216 ----------- 36 33
Healthy (17) 73 ---------- 90 ---
CL Bockmeyer et
al19
Sepsis non
survivor (6)
475 ----------- 20 99
ICU control(24) 175 41 166
R A Reiter et al17 Endotoxin
injected healthy
259 ------------ 64 81
Healthy 86 108 239
T Matsuyama et al20 Severe AH 806 -------- 24 110
100 -------- 107
Our study 756 570 ---------- 110
Platelet count expressed inx103/µL, AH- alcoholic hepatitis
In a study by Reuken et al21 when correlation matrix analysis was done a negative correlation
between platelet count and vWf Ag (-0.067) level and vWf activity (r -0.157) but was not
strong and statistically significant. In our study also there was a negative correlation noted
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between platelet count and vWfAg (-0.136) and vWf activity (-0.165) but was not strong and
significant.
There was a strong significant positive correlation noted between vWf Ag and vWf activity in
this study.
When ROC was plotted for MELD, vWf Ag D1 and vWf activity D1 AROC was fair for MELD
(0.744) and was poor for vWf Ag and activity (0.631 & 0.681). AROC was statistically
significant for MELD and vWF activity.
In a study by Monika Ferlitsch et al12 they studied vWf level as a predictor of survival in patients
with portal hypertension. In their study vWf Ag level predicted PHTN and CSPHTN
independent of CTP scores. A vWf cutoff value of ≥241% predicted CSPH. A cut off value of
≥315 significantly predicted decompensation and complications including mortality and was as
good as MELD in predicting mortality.
In a study by Vincenzo La Mura et al22 a study done to analyze vWf as predictor of clinical
outcome in patients with liver cirrhosis and portal hypertension. In patients with cirrhosis and
PHTN plasma and hepatic levels of vWF correlated with liver functions and HVPG.  Elevated
plasma levels of vWF predicted the prognosis of patients with liver cirrhosis, independently
of liver function and PHTN. A vWF value of 216 U/dl is a possible cutoff to differentiate two
different groups of patients with cirrhosis with a different probability of survival free of PHTN-
related complications/events and of liver transplantation.
They concluded that vWF is a promising endothelial-derived molecule to be taken into account
to improve prognostic models in patients with cirrhosis and PHTN.
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In our study when ROC curve was analyzed vWf activity was significantly predicting the
survival and vWf Ag had trend towards the same when compared to MELD.
A vWf Ag cut off of 529 had 84% sensitive and 33% specific and vWf activity cut off value of
402 had 79% sensitivity and 33% specificity.
89
Summary and conclusions for study objective 1.
 Coulter platelet count was lesser than manual platelet counts in all different study groups
 Corrected difference in platelet count in cryptogenic CLD (including NCIPH) with portal
hypertension patients was significantly higher compared to healthy controls
 Mean platelet volume was increased in all study groups and was significantly higher in
cryptogenic CLD (including NCIPH) with portal hypertension patients compared to
healthy controls
 But for 3 study groups (EHPVO, aplastic anemia and ITP), platelet clumping was noted
in all other study groups (in 11% – 18% of subjects) (including in 10% of healthy
controls). There was no significant difference noted in platelet clumping in cryptogenic
CLD with portal hypertension (including NCIPH) compared to other groups
 Immature platelet fraction was significantly increased in those with liver disease
compared to healthy controls and was significantly correlating with mean platelet volume
 Significant negative correlation was noted between MPV and platelet count so also IPF
and platelet count
To conclude, we found higher manual platelet counts compared to coulter platelet counts in
patients with portal hypertension, thrombocytopenic syndromes due to hematological disorders
and in healthy controls.  The higher manual platelet counts are probably due to increased mean
platelet volume (such platelets with increased volume are probably not counted by the coulter as
platelets).  The increased platelet volume is probably due to release of immature platelets into the
circulation. Platelet clumping in the circulation was noted in only 10 – 18% of study subjects. It
is possible that in some of the study groups (for example in portal hypertension), platelet
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clumping occurs as endothelial sequestration in spleen and in liver (termed hypersplenism) and
not as free-floating platelet clumps in circulation. .
Summary and conclusions for study objective 2.
 Plasma von-Willebrand factor levels were significantly elevated in patients with acute-
on-chronic liver failure. These levels are much higher than that of plasma vWf levels
reported in patients with cirrhosis.
 Plasma vWf activity on Day 1 was significantly higher in those who had adverse in-
hospital outcome compared to those who survived.
 Plasma vWf activity on Day 1 correlated significantly with severity of ACLF, with a
trend towards predicting survival independent of MELD.
 As the number of organ dysfunction increased, plasma vWf activity increased
 There was a negative correlation noted between platelet count and vWf activity
To conclude, in patients with acute-on-chronic liver failure, we found markedly increased
plasma vWf levels (compared to that reported in patients with cirrhosis in previous studies).
Correlation between severity of acute-on-chronic liver failure along with negative correlation
with the platelet count with elevated plasma vWF level was noted. In addition, elevated plasma
vWf activity level on Day 1 showed a trend to be an independent predictor of in-hospital
mortality. It is possible that platelet thrombi formed by platelets adhering to vWf  on endothelial
surface leads to microcirculatory occlusion and worsening organ failure in liver and in other
affected organs in patients with acute on chronic liver failure, thus contributing to mortality in
these patients.
91
Bibliography
1. Goel A , B Ramakrishna, Madu K et al, Idiopathic noncirhhotic portal hypertension is an ongoing
problem in India, Hepatology; December 2011.
2. Nezam Afdhal, John McHutchison, Robert Brown et al, Thrombocytopenia associated with
chronic liver disease, Journal of Hepatology; 48 (2008) 1000–1007
3. M Uemura, Y Fujimura, saiho Ko et al, Determination of ADAMTS13 and its clinical significance
for ADAMTS13 supplementation therapy to improve survival in patients with decompensated
liver disease, International Journal of Hepatology, 2011.
4. Goel A, PL Alagammai, Sukesh C N et al, ADAMTS13 deficiency, despite well compensated liver
functions in patients with noncirrhotic portal hypertension, Indian Journal of Gastroenterology,
2014.
5. Masahito Uemura, Yoshihiro Fujimura, Masanori Matsumoto et al,Comprehensive analysis of
ADAMTS13 in patients with liver cirrhosis, Thrombosis and Haemostasis 2008; 99: 1019–1029.
6. The American Society of Hematology 2011- evidence based practice guideline for immune
thrombocytopenia
7. Marsh et al, Guidelines for the diagnosis and management of aplastic anemia, 2009, British
Journal of Hematology
8. Sukesh C Nair et al, Asymptomatic constitutional macrothrombocytopenia among West Bengal
blood donors, The Americ Journal of Medicine, 2002.
9. Sarin S K et al, Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific
Association for the Study of the Liver (APASL) -2014, Hepatology International, 2014 .
92
10. Vincent J L et al, The SOFA- sepsis related organ dysfunction assessment-score to describe organ
dysfunction/failure, Intensive Care Medicine , 1996
11. Richard Moreau, Rajiv Jalan, Pere Gines et al, Acute-On-Chronic Liver Failure Is A Distinct
Syndrome That Develops In Patients With Acute Decompensation Of Cirrhosis, Gastroenterology
2013;144:1426–1437.
12. Monika Ferlitsch,1 Thomas Reiberger,1 Matthias Hoke et al, von Willebrand Factor as New
Noninvasive Predictor of Portal Hypertension, Decompensation and Mortality in Patients With
Liver Cirrhosis, Hepatology, 2012;56:1439-1447
13. D. Ribatti and E. Crivellato, “Giulio Bizzozero and the discovery of platelets,” Leukemia Research,
vol. 31, no. 10, pp. 1339–1341,2007.
14. Kakali Ghoshal and Maitree Bhattacharyya, Overview of Platelet Physiology: Its Hemostatic and
Nonhemostatic Role in Disease Pathogenesis, e Scientific World Journal, 2014.
15. Kerstin Jurk, Ph.D.,1 and Beate E. Kehrel, Platelets: Physiology and Biochemistry, Seminars in
thrombosis and Hemostasis, 2005
16. Aina Rodríguez-Vilarrupla;1 Mercedes Fernández;1 Jaume Bosch, Current concepts on the
pathophysiology of portal hypertension, Annals of Hepatology 2007; 6(1): January-March: 28-36
17. Kaneda K, Ekataksin W, Sogawa M, ,t al. Endothelin-1-induced vasoconstriction causes a
significant increase in portal pressure of rat liver: localized constrictive effect on the distal
segment of preterminal portal venules as revealed by light and electron microscopy and serial
reconstruction, Hepatology 1998; 27: 735-47.
18. HitoshiMaruyama and Osamu Yokosuka, Pathophysiology of Portal Hypertension and
Esophageal Varices, International Journal of Hepatology,2012
19. Liang Shuo Hu, Jacob George, Jian Hua Wang, Current concepts on the role of nitric oxide in
portal, Hypertension,World J Gastroenterol 2013 March 21; 19(11): 1707-1717
93
20. Yasuko Iwakiri, Endothelial dysfunction in the regulation of portal hypertension, Liver
International. 2012 February ; 32(2): 199–213
21. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol. 2007;
46(5):927–934
22. Hernandez-Guerra M, Garcia-Pagan JC, Turnes J, et al. Ascorbic acid improves the intrahepatic
endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology. 2006;
43(3):485–491
23. Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, et al. Increased oxidative stress in cirrhotic rat
livers: A potential mechanism contributing to reduced nitric oxide bioavailability.
Hepatology.2008; 47(4):1248–1256
24. Lavina B, Gracia-Sancho J, Rodriguez-Vilarrupla A, et al. Superoxide dismutase gene transfer
reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. Gut. 2009; 58(1):118–125
25. Karaa A, Kamoun WS, Xu H, Zhang J, Clemens MG. Differential effects of oxidative stress on
hepatic endothelial and Kupffer cell eicosanoid release in response to endothelin-
1.Microcirculation. 2006; 13(6):457–466
26. Yeligar S, Tsukamoto H, Kalra VK. Ethanol-induced expression of ET-1 and ET-BR in liver
sinusoidal endothelial cells and human endothelial cells involves hypoxia-inducible factor-1alpha
and microrNA-199. J Immunol. 2009; 183(8):5232–5243
27. Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S. Endotoxin-induced maturation of MyD88-
deficient dendritic cells. J Immunol. 2001; 166(9):5688–5694
28. Arroyo AG, Iruela-Arispe ML. Extracellular matrix, inflammation, and the angiogenic response,
Cardiovasc Res. 86(2):226–235
94
29. Thiele GM, Duryee MJ, Freeman TL, Sorrell MF, Willis MS, Tuma DJ, et al. Rat sinusoidal liver
endothelial cells (SECs) produce pro-fibrotic factors in response to adducts formed from the
metabolites of ethanol. Biochem Pharmacol 2005;70:1593–1600.
30. Ashish Goel, Kadiyala Madhu, Uday Zachariah, A study of aetiology of portal hypertension in
adults (including the elderly) at a tertiary centre in southern India, Indian J Med Res 137, May
2013, pp 922-927
31. Ebby G Simon, A J Joseph, Biju George, Aetiology of paediatric portal hypertension experience of
a tertiary care centre in South India, Tropical Doctor, 2009; 39: 42–44
32. Jaime Bosch et al, Portal Hypertension and Its Complications, Gastroenterology, 2008;134:1715–
1728
33. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of
their clinical significance and need for clinical and laboratory research. J Hepatol 2007;46:727–
733.
34. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000;14:60D–
66D.
35. Markus Peck-Radosavljevic, Johannes Zacherl’, Y. Gloria Meng, Is inadequate thrombopoietin
production a major cause of thrombocytopenia in cirrhosis of the liver, Journal of Hepatoiogy
1991; 27: 121-131
36. Benjamin T Kile, Aging platelets stimulate TPO production, Nature Medicine volume 21  number
1, January 2015
37. Robert V. Schatken, Walton, N. Y, Hypersplenism a review and case report, Annals of Surgery,
1952.
38. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic”
thrombocytopenia. J Clin Invest 1966; 45: 645-57.
95
39. Ton Lisman and Robert J. Porte, Rebalanced hemostasis in patients with liver disease: evidence
and clinical Consequences, Blood, 12 August  2010, Volume 116
40. Armando Tripodi, Ph.D., and Pier Mannuccio Mannucci, The Coagulopathy of Chronic Liver
Disease, N Engl J Med 2011;365:147-56.
41. J. L. Moake, “Thrombotic microangiopathies,” New England Journal of Medicine, vol. 347, no. 8,
pp. 589–600, 2002
42. H. M. Tsai and E. C. Lian, “Antibodies to von Willebrand factor-cleaving protease in acute
thrombotic thrombocytopenic purpura,” New England Journal of Medicine, vol. 339, no. 22, pp.
1585–1594, 1998.
43. M. Matsumoto, H. Chisuwa, Y. Nakazawa et al., “Livingrelated liver transplantation rescues
reduced vWF-cleaving protease activity in patients with cirrhotic biliary atresia,”Blood, vol. 96,
p. 636a, 2000.
44. F. Schaffner and H. Popper, “Capillarization of hepatic sinusoids in man,” Gastroenterology, vol.
44, pp. 239–242, 1963
45. Y. Fujimura, M. Matsumoto, H. Yagi, A. Yoshioka, T. Matsui, and K. Titani, “Von Willebrand
factor-cleaving protease and Upshaw-Schulman syndrome,” International Journal of
Hematology, vol. 75, no. 1, pp. 25–34, 2002.
46. L. Albornoz, D. Alvarez, J. C. Otaso et al., “Von Willebrand factor could be an index of endothelial
dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide
levels,” Journal of Hepatology, vol. 30, no. 3, pp. 451–455, 1999.
47. K. Oka and K. Tanaka, “Intravascular coagulation in autopsy cases with liver diseases,”
Thrombosis and Haemostasis, vol. 42, no. 2, pp. 564–570, 1979
48. M. Uemura, Y. Fujimura, M. Matsumoto et al., “Comprehensive analysis of ADAMTS13 in
patients with liver cirrhosis,” Thrombosis and Haemostasis, vol. 99, no. 6, pp. 1019–1029, 2008.
96
49. X. Zheng, D. Chung, T. K. Takayama, E. M. Majerus, J. E. Sadler, and K. Fujikawa, “Structure of
von Willebrand factorcleaving protease (ADAMTS13), a metalloprotease involved in thrombotic
thrombocytopenic purpura,” Journal of Biological Chemistry, vol. 276, no. 44, pp. 41059–41063,
2001.
50. A. Bernardo, C. Ball, L. Nolasco, J. F. Moake, and J. F. Dong, “Effects of inflammatory cytokines
on the release and cleavage of the endothelial cell-derived ultralarge von Willebrandfactor
multimers under flow,” Blood, vol. 104, no. 1, pp. 100– 106, 2004.
51. H. Fukui, B. Brauner, J. C. Bode, and C. Bode, “Plasma endotoxin concentrations in patients with
alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay,”
Journal of Hepatology, vol. 12, no. 2,162–169, 1991.
52. M. Furlan, R. Robles, M. Galbusera et al., “Von Willebrand factor-cleaving protease in
thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome,” New England
Journal of Medicine, vol. 339, no. 22, pp. 1578–1584, 1998.
53. W. J. Cao, M. Niiya, X. W. Zheng, D. Z. Shang, and X. L. Zheng, “Inflammatory cytokines inhibit
ADAMTS13 synthesis in hepatic stellate cells and endothelial cells,” Journal of Thrombosis and
Haemostasis, vol. 6, no. 7, pp. 1233–1235, 2008.
54. R. A. Claus, C. L. Bockmeyer, M. Sossdorf, and W. L¨osche, “The balance between von-
Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and
development of organ failure?” Current Molecular Medicine, vol. 10, no. 2, pp. 236–248, 2010
55. Rajiv Jalan, Pere Gines, Jody C Olson, Acute-on chronic liver failure, Journal of Hepatology
Volume 57, Issue 6, December 2012, Pages 1336–1348
56. Danielle Adebayo, Vincenzo Morabito, Rajiv Jalan, Acute on chronic liver failure applying the
PIRO concept, EMJ Hepatol. 2013;1:38-43.
97
57. Andrew Osei-Bimpong, The effect of storage on the clinical utility of the immature platelet
fraction, Volume 14, Issue 2 (01 April 2009), pp. 118-121
58. Hong Hong, Wenbin Xiao, Robert W. Maitta, Steady Increment of Immature Platelet Fraction Is
Suppressed by Irradiation in Single-Donor Platelet Components during Storage,PLOS ONE Jan
2014
59. M. Zandecki, f. Genevieve, j. Gerard, spurious counts and spurious results on Haematology
analysers: a review. Part i: platelets, International Journal of Laboratry Hematology, 2006
60. Anton h. Sutor, Astrid Grohmann, Klaus Kaufmehl et al, Problems with platelet counting in
thrombocytopenia. A rapid manual method to measure low platelet counts, Seminars in
Thrombosis and Hemostasis,  volume 27, number 3 2001
61. Carol Briggs, Stefan Kunka, Dan Hart et al, Assessment of an immature platelet fraction (IPF) in
peripheral thrombocytopenia, British Journal of Hematology, 2004
62. Robert W Maitta et al, Immature Platelet Fraction: Coming of Age of an Underutilized Test in the
setting of Thrombotic Thrombocytopenic Purpura, J Blood Disorders Transfusion, 2014
63. Sehgal K et al, Reference range evaluation of complete blood parameters with emphasis on
newer research parameters on the complete blood count analyzer, Sysmex-XE 2100  Indian J
Pathol Microbiol 2013;56:120-4
64. T. Nomura, Y. Kubota, A. Kitanaka, Immature platelet fraction measurement in patients with
chronic liver disease: a convenient marker for evaluating cirrhotic change, International Journal
of Laboratory Hematology 2010
65. Issac Pons, Manuel Monteagudo, Gianni Lucchetti et al, Correlation between immature platelet
fraction and reticulated platelets. Usefulness in the etiology diagnos, is of thrombocytopenia,
European Journal of Hematology 2010.
98
66. Thomas D. Boyer and Shahid Habib et al, Big spleens and hypersplenism: fix it or forget it, Liver
International, 2014.
67. Amol Ajit Khot & Piyush Somani & Pravin Rathi et al, Prognostic factors in Acute-on-chronic liver
failure, a prospective study from western India, Indian Journal of Gastroenterology, 2014y
68. Ashish Kumar Jha, Sandeep Nijhawan , Ramesh Roop Rai etal, Etiology, clinical profile and
inhospital mortality in patients with acute on chronic liver failure, Indian Journal of
Gastroenterology, 2013
69. Hitendra Garg, Ashish Kumar, Vishal Garg et al, Hepatic and systemic hemodynamic
derangements predict early mortality and recovery in patients with acute-on-chronic liver
failure, Journal of Gastroenterology and Hepatology (2013) 1361–1367
70. Swastik Agrawal, Ajay Duseja, Tarana Gupta, Simple organ failure count versus CANONIC grading
system for predicting mortality in acute-on-chronic liver failure, Journal of Gastroenterology and
Hepatology 30 (2015) 575–581
71. Vishal Garg, Hitendra Garg, Arshi Khan, Granulocyte Colony–Stimulating Factor Mobilizes Cd34_
Cells And Improves Survival Of Patients With Acute-On-Chronic Liver Failure, Gastroenterology
2012;142:505–512
72. J . A. Kremer Hovinga, S . Zeerleder, P. Kessler, Adamts-13, Von Willebrand Factor And Related
Parameters In Severe Sepsis And Septic Shock, Journal Of Thrombosis And Haemostasis, 5:
2284–2290
73. J . J . J . Hulstein, P. J . Van Runnard Heimel, A. Franx, Acute Activation Of The Endothelium
Results In Increased Levels Of Active Von Willebrand Factor In Hemolysis, Elevated Liver
Enzymes And Low Platelets (HELLP) Syndrome, Journal Of Thrombosis And Haemostasis, 4:
2569–2575
99
74. Ton Lisman, Tamara N. Bongers, Jelle Adelmeijer, Elevated Levels Of Von Willebrand Factor In
Cirrhosis Support Platelet Adhesion Despite Reduced Functional Capacity, Hepatology,
2006;44:53-61
75. Rosemarie A. Reiter1, Katalin Varadi, Peter L. Turecek, Changes in ADAMTS13 (von-Willebrand-
factor-cleaving protease) activity after induced release of von Willebrand factor during acute
systemic inflammation, Thrombosis Haemostasis 2005; 93: 554-8
76. Greg C. G. Hugenholtz,1 Jelle Adelmeijer,1 Joost C. M. Meijers, An Unbalance Between von
Willebrand Factor and ADAMTS13 in Acute Liver Failure: Implications for Hemostasis and Clinical
Outcome, Hepatology, 2013;58:752-761
77. Clemens L. Bockmeyer,1 Ralf A. Claus,1 Ulrich Budde, Inflammation-associated ADAMTS13
deficiency promotes formation of ultra-large von Willebrand factor, Haematologica, the
Hematology journal  2008; 93(1)
78. Tomomi Matsuyama, Masahito Uemura, Masatoshi Ishikawa, Increased von Willebrand Factor
Over Decreased ADAMTS13 Activity May Contribute to the Development of Liver Disturbance
and Multiorgan Failure in Patients With Alcoholic Hepatitis, Alcoholism: Clinical and
Experimental Reasearch, Jan 2007.
79. Philipp A. Reuken, Anna Kussmann, Michael Kiehntopf, Imbalance of von Willebrand factor and
its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced
cirrhosis, Liver International, 2014
80. Vincenzo La Mura, Juan Carlos Reverter, Alexandra Flores-Arroyo, Von Willebrand factor levels
predict clinical outcome in patients with cirrhosis and portal hypertension, Gut
2011;60:1133e1138
100
81. R Garcia Martinez, J O’Brien, L Noiret, N Davies et al, Albumin restores renal blood flow
autoregulation  in patients with refractory ascites and acute-on-chronic liver failure through
stabilization of endothelial function, Gut July 2012 Vol 61 Suppl 2
82. Derek A. Mann , Fiona Oakley, Serotonin paracrine signaling in tissue fibrosis, Biochimica et
Biophysica Acta 1832 (2013) 905–910
83. Patrick Starlinger, Alice Assinger, Stefanie Haegele, Evidence for serotonin as a relevant inducer
of regeneration after liver resection in humans, Hepatology, 2014;60:257-266
84. Tian Y, Graf R, El-Badry AM, Lesurtel M, Furrer K, Moritz W, et al. Activation of serotonin
receptor-2B rescues small-for-size liver graft failure in mice. Hepatology, 2011;53:253-262.
85. Mickael Lesurtel, Dimitri A. Raptis, Emmanuel Mellou et al, Low platelet count after liver
transplantation predict early post transplant survival-The 60-5 criteria, Liver Transplantation,
20:147-155, 2014
86. Richard G. Ruddell, Fiona Oakley, Ziafat Hussain, A Role for Serotonin (5-HT) in Hepatic Stellate
Cell Function and Liver Fibrosis, The American Journal of Pathology, Vol. 169, No. 3, September
2006
87. Dorde M Culafic, Dusko S Mirkovic, Plasma and platelet serotonin levels in patients with
cirrhosis, World J Gastroenterol 2007 November 21; 13(43): 5750-5753
88. Alan T. Nurden, Paquita Nurden, Inherited thrombocytopenias, haematologica/the hematology
journal, 2007; 92(09)
89. Shilpita Karmakar, Sutapa Saha1, Debasis Banerjee, Differential proteomics study of platelets in
asymptomatic constitutional macrothrombocytopenia: altered levels of cytoskeletal proteins,
European Journal of Haematology, 2014 94 (43–50)
90. Rajiv Jalan, Pere Gines, Jody C Olson, Acute-on chronic liver failure, Journal of Hepatology 2012
vol. 57, 1336–1348
Abbreviations
5-HT- 5 Hydroxy Tryptamine
AASLD- American Association For The Study Of Liver Diseases
Ach- Acetyl Choline
ACLF- Acute-On-Chronic Liver Failure
ADAMTS13- A Disintegrin And Metalloproteinase With A Thrombospondin Type 1 Motif,
Member 13
ADP-Adenosine Di Phosphate
AKI- Acute Kidney Injury
ANA- Anti Nuclear Antibodies
APACHE- Acute Physiology And Chronic Health Evaluation
APASL- Asia Pacific Association For The Study Of Liver
aPTT- Activated Partial Thromboplastin Time
AROC- Area under Receiver Operating Characteristic Curve
AT- Angiotensin
ATP- Adenosine Triphosphate
ATT- Anti Tubercular Therapy
CANONIC- CLIF Acute-on-chronic liver failure in Cirrhosis study
CLD- Chronic Liver Disease
CMT- Constitutional Macrothrombocytopenia
CO- Carbon Monoxide
CTP- Child Pugh Turcott
EASL-European Association For The Study Of Liver
EDTA- Ethanolamine Tetradecyl Trisodiumcitrate
EHPVO- Extrahepatic Portal Vein Obstruction
ET- Endothelin
GI- Gastro Intestinal
HBV- Hepatitis B
HCV- Hepatitis C
HE- Hepatic Encephalopathy
HELLP- Hemolysis Elevated Liver enzymes Low platelet
HSC- Hepatic Stellate Cells
IL- Interleukin
INR- International Normalized Ratio
IPF- Immature Platelet Fraction
ITP- Idiopathic Thrombocytopenic Purpura
LPS- Lipopolysccaride
LSEC- Liver Sinusoidal Endothelial Cells
LTX-Liver Transplant
MAO- Mono Amine Oxidase
MARS- Molecular Adsorbent Recycling System
MDA- Mono Dialdehyde
MELD- Model For End Stage Liver Disease
miRNA- Micro Ribo Nucleic Acid
MPV- Mean Platelet Volume
NAFLD- Non Alcoholic Fatty Liver Disease
NCIPH-Noncirrhptic Intrahepatic Portal Hypertension
NE- Nor Epinephrine
NO- Nitric Oxide
PG- Prostaglandin
PHTN-Portal Hypertension
PT- Prothrombin Time
ROC- Receiver Operating Characteristic curve
SEC-Sinusoidal Endothelial Cell
SERT- Serotonin Reuptake Transporter
SIRS- Systemic Inflammatory Response Syndrome
SOFA- Sequential Organ Dysfunction Assessment
TGF- Transforming Growth Factor
TIPSS- Transjugular Intrahepatic Portosystemic Shunt
TLR- Toll Like Receptor
TMA- Thrombotic Micro Angiopathy
TNF- Tumor Necrosis Factor
T-PA- Tissue Plasminogen Activator
TPO- Thrombopoietin
TTP- Thrombotic Thrombocytopenic Purpura
TXA- Thromboxane
UL vWf- Ultra Large Von Willebrand Factor
vWf Ag- von Willebrand factor antigen
vWf- Von Willebrand Factor
Analysis of platelet clumping in portal hypertension
Identification data
Name : ________________________
ID No: _________________________
Contact No: ____________________
Important dates
Date of proforma entry: _________
Date of visit to CMC: ____________
Date of liver biopsy: _____________
Initial presentation
_____________________________
_____________________________
Present symptoms:
_____________________________
_____________________________
Associated comorbidities
H/O drugs: ____________________
Cardiac disease: ________________
Hematological disease: __________
DM/HTN: _____________________
Any other: ____________________
Study participant No: __________________
Case/control: ________________________
Occupation: __________________________
Height: ______ cms     Weight: _______ Kg
Examination : _________________________
_____________________________________
Upper GI scopy:
Date: ________________
Esophageal varices: ______________________
Gastric varices: __________________________
Ultrasound/Doppler abdomen
Liver size: _____________________________
Surface/volume: _______________________
Portal/hepatic veins: ____________________
Diagnosis/CTP Score
______________________________________
______________________________________
Samples to be sent
 Blood in citrate(3ml) and EDTA(2ml)
tubes for platelet count
 Blood in EDTA tube (4ml)
Study of von Willebrand factor as predictor of in-hospital survival in patients with acute
on chronic liver cell failure
Study subject No :-----------------------
Name :--------------------------------------
Hospital number: ------------------------
Contact no :-------------------------------
Presenting symptoms: -----------------
----------------------------------------------
Alcoholism –significant/not significant
Clinical findings
Temperature :--------------------------
Heart rate: ------------------------------
Respiratory rate: -----------------------
GCS : ---------------------------------------
SBP/MAP : --------------------------------
Mottling /capillary refilling; Yes/No
Inotropes – dopamine/epinephrine/nor
epinephrine
Urine output : --------------------------
Comorbidity:
DM/HTN: --------------------------------
Any drugs: -------------------------------
Investigations:
Varices: ----------------------------------
Ultrasound : -----------------------------
BBVS; HBsAg / HCV/HIV
IgM-HAV/HEV : ------------------------------------------
ABG- PaO2-----, PaCo2-----, lactates-----,P/F-----
GRBS: -----------------------------------------------------
TLC/BF: ---------------------------------------------------
Hb : -------------------------------------------------------
Delta platelet : -----------------------------------------
PT/INR : ---------/--------; APTT-------------
LFT : -----------------------------------------------------
Creatinine: -----------------------------------------------
Cultures: blood/urine/ascetic fluid
MELD : -----------------------------------------------------
CTP :  A/ B/ C
Sepsis : Yes/ No
FINAL DIAGNOSIS: ---------------------------------------
----------------------------------------------------------------
Etiology: ---------------------------------------------------
Study of von Willebrand factor as predictor of in-hospital survival in patients with acute
on chronic liver cell failure
SOFA score:
At admission; ----------
H.no. manual coulter MPV clumps manual coulter MPV
902036B 268000 238000 8.5 0 242000 186000 8
834880B 220000 183000 8.1 0 204000 163000 7.9
279795F 212000 199000 9 0 191000 159000 8.1
260518F 355000 323000 6.9 0 324000 260000 6.5
264634F 281000 248000 6.9 0 259000 199000 6.4
946978c 192000 184000 9.9 0 126000 129000 9.3
079688d 124000 142000 8.5 0 96000 86000 8.3
503938d 292000 235000 7.9 0 168000 158000 7.5
764511f 151000 132000 11 0 86000 81000 10.1
635724f 236000 247000 8.7 0 181000 199000 8.3
763483c 188000 197000 9.1 0 142000 147000 8.6
553297b 253000 272000 8 0 181000 220000 7.4
685843f 188000 124000 14.2 0 191000 99000 13.3
093089f 312000 337000 7.8 1 204000 244000 7.3
853165c 384000 364000 7.6 0 357000 318000 6.9
450073d 370000 323000 8.4 1 254000 215000 7.8
348715a 290000 271000 7.6 0 253000 227000 7.2
307655d 260000 238000 9.8 0 200000 188000 8.9
080473b 300000 263000 8.6 0 248000 140000 7.8
014010a 290000 262000 8.8 0 260000 211000 8.7
019155c 68000 56000 12.1 0 24000 9000 9.1
244405 56000 47000 11.2 0 21000 15000 8
167857d 91000 66000 8.8 0 66000 53000 7.8
313525b 48000 42000 9.3 0 36000 35000 8.8
788009D 142000 126000 9.9 1 94000 88000 9.1
089521F 54000 43000 9.9 0 48000 33000 8.7
089521f 54000 43000 9.9 0 48000 33000 8.7
712575f 115000 71000 11.7 0 82000 57000 10.5
646927f 112000 99000 9.5 0 68000 57000 8.6
693740f 81000 50000 10.3 0 42000 35000 8.8
692695f 165000 125000 7 0 108000 91000 6.5
699699f 68000 62000 7 0 58000 46000 6.6
699356d 131000 93000 8.9 0 102000 94000 8.3
693226f 153000 121000 9.4 0 146000 92000 8.2
648000f 63000 39000 10.8 1 48000 31000 9.5
639590f 62000 50000 8.3 0 46000 36000 7.5
379830f 68000 56000 9.2 0 43000 39000 8.1
428378f 80000 74000 8.7 1 60000 53000 7.6
607318f 108000 92000 8.6 0 78000 61000 8
702248f 85000 69000 11.5 0 68000 55000 10.4
711056f 64000 42000 10.8 0 39000 28000 8.7
064554f 112000 94000 8.9 0 82000 75000 8.1
835371d 76000 84000 8.8 0 39000 48000 8.3
702105f 120000 130000 8.7 1 72000 99000 8.7
714589f 17000 21000 10.6 0 8000 16000 9
718000f 82000 101000 9 0 65000 67000 8.8
711476f 32000 19000 9.2 0 16000 18000 9.7
385667f 28000 19000 10.4 0 13000 18000 10.6
631215f 62000 38000 11.7 1 58000 29000 11.4
280962F 240000 179000 9.9 1 150000 12000 10
790782F 32000 41000 10.9 0 32000 34000 8.7
394475F 69000 48000 9.9 0 59000 50000 9.6
371462F 108000 96000 7.9 0 94000 90000 7.8
712962F 38000 47000 9.6 0 31000 36000 8.4
212840F 53000 44000 8.6 0 53000 44000 8.6
791656F 70000 82000 11.2 0 76000 70000 10.6
395057D 43000 30000 9 0 48000 26000 8.8
018241F 94000 63000 11.5 1 52000 42000 9.8
301248F 64000 59000 16 0 53000 43000 12.7
492943F 75000 52000 10 0 80000 55000 10.2
607484F 66000 29000 11.1 1 48000 20000 8.9
711476F 32000 19000 9.2 0 16000 18000 9.7
876572C 15000 5000 9.9 0 12000 5000 10.3
003887G 30000 20000 11.4 0 18000 18000 9.6
093892F 39000 15000 11 0 12000 8000 8.7
714416F 90000 107000 10 0 80000 88000 9.1
773439F 70000 45000 10.2 0 50000 41000 9.9
688818D 92000 83000 11.2 0 54000 62000 8.8
607298F 176000 159000 9.4 0 143000 110000 8.5
475356F 228000 172000 12 1 163000 103000 11
659692f 33000 17000 11.8 0 20000 4000 11.7
912383c 99000 85000 11 0 75000 59000 9.8
678972f 138000 113000 8.5 0 142000 88000 8.1
687696F 75000 55000 9.9 1 61000 43000 8.8
674737f 136000 143000 8 0 130000 115000 7.4
697066f 116000 90000 8.2 0 68000 69000 7.4
709572f 79000 58000 8.4 0 56000 44000 7.7
704092f 47000 28000 9.1 0 34000 20000 8.4
725559D 120000 86000 12.5 0 110000 70000 11.9
712821f 56000 41000 9.7 0 52000 33000 8.6
698417f 110000 47000 10.9 0 70000 42000 10.5
704390f 85000 52000 9.8 0 76000 38000 8.7
718088f 64000 60000 10 0 37000 44000 9.2
986857d 42000 49000 11.3 0 36000 41000 11.3
713948f 144000 166000 7.4 0 116000 127000 7.1
184593d 72000 84000 11.3 0 64000 69000 10.2
751084f 194000 153000 10.4 1 186000 114000 10.2
782733f 97000 85000 10.8 0 92000 88000 9.7
729364f 105000 86000 9 0 98000 63000 8.5
753686f 80000 99000 8.9 0 61000 76000 8.3
625442f 62000 44000 11.7 0 46000 35000 10.1
157046f 154000 136000 10.1 1 118000 99000 9.1
139164f 32000 39000 7.9 0 42000 37000 8
945835a 98000 91000 8.2 1 80000 60000 7.9
897252F 85000 70000 10.8 0 65000 50000 9.3
912487F 59000 56000 9.2 0 53000 46000 8.3
751235F 109000 103000 9 0 96000 83000 8.3
249034D 47000 16000 12.6 0 34000 13000 12.7
615107F 44000 38000 10.7 0 27000 25000 9.2
875579F 89000 85000 10.4 0 66000 63000 9.9
418036D 95000 60000 10.7 0 56000 41000 8.8
865156F 48000 22000 9.5 0 39000 20000 8.8
863649F 182000 154000 10 0 152000 147000 9
857190F 138000 126000 8.9 0 94000 79000 8.7
852708F 16000 17000 11.8 0 19000 15000 11
841629F 36000 32000 11.9 0 18000 30000 11.1
854912F 68000 85000 9 0 38000 60000 9
852765F 185000 180000 9 0 166000 159000 8
902911F 41000 34000 7.4 0 26000 21000 5.8
863531D 110000 78000 11 0 84000 64000 10.1
712821f 56000 41000 9.7 0 52000 33000 8.6
841629F 67000 40000 9.9 0 48000 27000 9.9
462820D 40000 32000 10.7 0 33000 27000 9.8
754233F 148000 168000 9.1 1 132000 129000 8.6
872933d 67000 37000 12.4 0 43000 26000 12.6
341343f 37000 32000 9 0 38000 26000 8.4
901002d 158000 125000 8.3 0 102000 98000 8
850023f 26000 14000 11.3 0 18000 8000 9.1
831671f 148000 128000 9.6 0 135000 107000 8.5
400177c 66000 52000 11.6 0 54000 35000 10.9
660437d 48000 48000 9.4 0 42000 35000 8.4
218345F 45000 35000 10.5 0 22000 31000 9.6
000930c 90000 84000 8.8 0 70000 63000 8.2
889741F 135000 129000 10.8 0 110000 96000 8.6
043487G 125000 147000 9.8 0 120000 117000 9.1
035169G 30000 28000 11 0 32000 27000 7.3
920538F 44000 29000 8.6 0 42000 24000 8
021920G 30000 32000 7.3 0 40000 30000 6.7
022382G 15000 7000 12 0 9000 7000 11.4
000827G 15000 9000 10.5 0 7000 9000 9.6
915622F 15000 15000 10 0 4000 6000 8.8
879719F 15000 9000 8.6 0 9000 4000 3.4
686371D 15000 10000 4.8 0 9000 16000 11.2
021539G 75000 67000 8.8 0 62000 60000 7.5
004325G 165000 152000 13.6 0 128000 120000 11.3
016345G 46000 33000 7.6 0 33000 28000 7.1
862676F 80000 4000 10.3 0 6000 4000 8.8
853365F 6000 4000 8.5 0 5000 2000 12.4
037020G 60000 34000 13.1 0 30000 35000 14.9
041956G 60000 8000 10.6 0 30000 7000 11.4
035967G 45000 26000 13.3 0 30000 18000 8.6
917994F 15000 7000 8.5 0 15000 2000 11.6
037142G 15000 13000 9.9 0 15000 6000 9.5
038897G 15000 4000 8.4 0 15000 2000 9.5
920047F 15000 14000 8.5 0
917939F 30000 19000 10.5 0 30000 19000 9.5
041475G 15000 16000 6.1 0 15000 16000 6.8
040913G 15000 1000 12 0 15000 2000 10.4
041081G 15000 14000 9.3 0 15000 5000 11.1
040644G 15000 19000 13.1 0 15000 15000 10
026390G 45000 73000 11.1 0 15000 21000 8.7
027612G 25000 29000 10.6 0 25000 22000 8.4
034874G 78000 63000 10.2 0 14000 22000 8
025104G 23000 40000 8.4 0 14000 22000 8
037502G 10000 8000 7.3 0 90000 11000 6.6
037598G 7000 9000 8.9 0 5000 4000 9.7
917439F 68000 69000 10 0 57000 72000 8.6
923373F 12000 13000 8.5 0 8000 7000 8.7
065033G 14000 17000 10 0 13000 14000 8.2
273580C 12000 11000 13 0 8000 10000 10.2
044061G 12000 19000 12.4 0 8000 10000 9.2
048721G 13000 19000 9.6 0 16000 14000 8
030937G 16000 29000 11.2 0 12000 13000 11.8
718506F 13000 16000 9.6 0 7000 8000 11
010672D 33000 16000 11.7 0 20000 14000 10.8
873369D 5000 4000 12.6 0 5000 3000 11.4
215029M 125000 76000 14.2 0
344471F 128000 84000 13 0
985940D 185000 92000 15.8 0
672929D 153000 91000 13.3 0
668243D 155000 97000 14.6 0
028597G 132000 81000 16.2 0
175809D 128000 70000 14.4 0
042243G 138000 71000 14.8 0
991502D 132000 79000 15 0
036337G 58000 38000 13.5 1
854954D 96000 58000 13.7 0
042600G 102000 86000 14.6 0
044060G 98000 65000 14.5 0
043059G 103000 51000 13.6 1
007446G 98000 54000 15.3 0
044082G 123000 83000 13 0
045890G 153000 87000 13.1 0
813361F 128000 64000 13.7 0
043025G 121000 76000 13.8 1
914227C 158000 81000 13.6 0
clumps PPP serptoninplatelet serptoninAge Sex CTP GROUP SPLEEN SIZE
1 11.134 0.774 31 0 1
0 33.49 1.25 37 0 1
0 10.436 0.088 29 1 1
0 6.901 0.505 31 1 1
0 14.43 7.624 31 1 1
0 28 0 1
0 27 0 1
0 22 0 1
1 63 1 1
1 32 1 1
0 34 0 1
0 40 1 1
0 21 1 1
1 22 1 1
0 29 0 1
1 29 0 1
0 45 0 1
0 30 1 1
0 25 1 1
0 40 0 1
0 2.227 0.499 60 1 1 2 14.1
0 0.372 0.344 65 0 3 2 13.6
0 0.392 0.16 60 0 1 2 10.5
0 1.875 0.041 36 1 2 2 19.6
1 51.038 2.39 58 1 1 2 11
0 38 1 1 2 17.1
0 38 1 1 2 17
0 42 1 1 2 13.3
0 1.309 1.337 64 1 1 2 11.4
0 1.948 0.167 50 1 3 2 14
0 56 1 1 2 17
0 0.429 0.226 58 1 3 2 15.2
0 47 0 2 2 14.6
0 52 1 1 2 12.8
0 40 1 2 2 23.7
0 0.15 1.698 30 1 1 2 15.4
0 31 1 1 2 16.9
0 0.161 0.251 22 0 1 2 12.3
0 0.106 1.795 25 1 1 2 21.5
0 0.023 0.386 66 0 2 2 16.2
0 0.126 0.188 10 1 1 2 19.5
0 0.081 0.523 48 0 1 2 14.5
0 57 1 3 2 11.6
1 63 1 1 2 19.5
0 19 1 2 2 15.2
0 43 1 2 2 12.2
0 21 1 1 2 24.6
0 64 1 3 2 13.8
1 45 1 1 2 14.5
1 54 1 1 2 12.5
0 46 1 1 2 12
0 20 1 1 2 19.3
0 73 1 1 2 10.8
0 59 1 1 2 18.5
0 20 1 1 2 23
0 66 0 1 2 12.5
0 45 1 1 2 23.5
1 43 1 1 2 15.2
0 38 0 1 2 16.6
0 55 1 1 2 20
1 26 1 1 2 17.4
0 23 1 1 2 24.6
0 30 1 1 2 10.9
0 38 1 1 2 26.5
0 43 1 1 2 21
0 62 1 1 2 11.5
0 50 1 2 2 14.3
0 50 0 1 2 16.9
0 51 1 1 2 12.8
1 36 1 1 2 9.2
0 0.786 0.103 24 1 1 3 21
0 0.454 0.267 57 1 1 3 9.9
0 7.003 3.059 37 1 1 3 15.2
0 11.317 1.535 33 1 2 3 12.3
0 0.494 0.062 64 1 3 3 8.9
0 44 0 1 3 14
0 0.617 2.138 43 1 3 3 15.2
0 0.011 0.05 55 0 3 3 16
0 60 1 1 3 10
0 46 1 1 3 21.4
0 29 1 2 3 16.7
0 37 1 2 3 15.5
0 56 0 2 3 14.4
0 40 1 2 3 15
0 54 1 3 3 11.9
0 48 1 1 3 12.8
0 45 1 2 3 14.2
0 60 1 3 3 13
0 49 1 2 3 13.3
0 49 1 2 3 18
0 54 0 2 3 16
1 51 1 1 3 10.7
0 47 0 3 3 12.9
1 57 0 3 3 13.2
0 38 1 1 3 13
0 74 1 3 3 10.6
0 47 1 1 3 15
0 52 1 1 3 18.6
0 57 1 1 3 12.3
0 38 1 2 3 15.7
0 48 1 1 3 14.6
0 41 1 1 3 18
0 50 1 1 3 9
0 51 1 1 3 14
0 41 1 2 3 13
0 45 1 3 3 12.8
0 24 1 1 3 14.3
0 41 1 3 3 12.8
0 53 0 3 3 13.2
0 4.472 1.474 23 1 1 3 13.2
0 46 1 1 3 21.4
0 46 1 1 3 12.7
0 33 1 1 3 20
1 65 1 3 3 10.8
0 1.779 0.279 38 1 1 4 18.6
0 3.851 0.257 34 1 1 4 20.9
0 10.7 0.652 33 0 1 4 14.9
0 20 0 1 4 20.9
0 13 1 1 4 14
0 20 1 1 4 13
0 18 1 1 4 17.4
0 20 0 1 4 17
0 41 0 1 4 14.3
0 55 1 2 4 13.9
0 34 1 1 4 17
0 18 1 1 4 20.2
0 27 1 1 4 23.5
0 43 1 5
0 7 0 5
0 64 1 5
0 10 0 5
0 14 0 5
0 9 0 5
0 47 0 5
0 30 0 5
0 51 1 5
0 56 1 5
0 24 1 5
0 33 1 5
0 23 1 5
0 18 1 5
0 35 0 5
0 40 0 5
0 23 0 5
37 0 5
0 27 1 5
0 50 0 5
0 28 0 5
0 59 0 5
0 6 0 5
0 28 1 5
0 16 1 5
0 40 0 5
0 36 1 5
0 69 1 5
0 19 0 5
0 37 1 5
0 38 0 5
0 49 0 5
0 18 0 5
0 18 1 5
0 29 1 5
0 59 1 5
0 38 0 5
0 58 1 5
0 24 0 5
40 0 6
68 0 6
51 1 6
47 1 6
61 1 6
54 1 6
40 1 6
22 0 6
64 1 6
66 1 6
66 1 6
58 1 6
46 0 6
58 1 6
49 1 6
25 1 6
37 1 6
60 1 6
30 1 6
28 1 6
HOSP NO PLATELET COUNT MPV IPF SPLEEN SIZEGROUP(1-crypto,2-hb/cv,3-healthy,4-aplastic,5-itp)AGE SEX
946690F 176000 12 6.2 13 1 63 0
165928G 87000 6.7 20 1 38 1
945910F 116000 11.4 3.7 14.9 1 36 1
146759D 52000 10.5 2.3 10 4 41 1
163102G 48000 11.6 3 22 1 50 1
947119F 95000 8 12.7 2 54 1
445840F 139000 12.4 4.1 12.9 2 64 1
487116F 129000 10.3 6 14.1 1 27 1
297798B 293000 5.8 25.8 1 47 0
125348D 57000 17.3 18.2 2 57 1
112986F 85000 12.3 4.4 13 1 55 1
074055G 43000 7.8 24.9 1 28 1
857347C 109000 2.9 12 2 62 0
158225G 40000 12.6 2 13.2 1 51 1
945677F 15000 14.1 13.6 2 43 0
932013D 698000 9.7 4.2 1 33 1
945334F 147000 9.9 2.9 12.5 1 81 0
335866F 143000 13.5 10.2 12.1 2 60 1
946321F 116000 11.8 6.7 17.5 1 55 1
945677F 19000 13.7 13.6 2 43 0
942635F 93000 12.3 6.2 15.8 1 24 0
148636G 68000 9.8 4 12 2 63 1
946090F 282000 9.7 2.4 9.6 1 68 0
948001F 127000 10.1 2.9 2 51 1
915029F 102000 11.5 4 12.1 1 26 0
156193G 23000 10.7 7.1 22.4 1 41 0
756752F 31000 9.9 1.2 15 1 54 0
279795F 240000 10.7 4.7 3 30 1
417136A 318000 11.1 4.2 3 30 0
291751B 262000 10.2 1.8 3 40 0
114589F 399000 9.2 1.3 3 24 0
496784D 304000 10.8 6.1 3 32 1
440682C 320000 9.9 3.1 3 27 1
249658A 369000 9.3 0.8 3 33 0
715181D 348000 10 2.7 3 28 0
843237A 291000 9.9 3.2 3 42 0
211606D 334000 10.5 2.7 3 36 1
208797C 344000 10.6 3.1 3 33 0
445175B 379000 10.4 2 3 38 0
268017D 312000 10.7 3 3 23 1
307655D 325000 11.1 4.2 3 28 1
364685F 37000 13.1 6.4 16.9 1 39 1
561488D 242000 11.1 3.7 13.5 1 53 0
607223F 397000 9.1 1.1 3 29 1
625631B 305000 10.5 3.5 3 35 1
816713D 86000 13.7 9.9 12.1 2 49 0
015027G 426000 9.8 1.9 3 29 0
015108G 227000 11.7 5.5 3 27 1
015204G 219000 11.8 4.9 3 29 1
926801F 131000 11.9 2.9 10 2 51 1
005414G 20000 13 21 1 49 0
166723G 5000 2.2 4 23 1
163372G 14000 25.2 5 23 0
506210C 43000 5.6 20.1 2 40 1
715009D 70000 13 8 15.7 2 34 1
167442G 322000 12.3 8.3 1 54 0
024841G 77000 12.5 5.6 12.6 2 50 1
740531F 34000 11.5 5 20.3 1 47 0
775066F 118000 28.3 10 1 54 1
947291F 72000 13.4 5 42 0
CTP
1
3
3
2
1
2
1
1
3
1
1
1
1
3
2 *
3
2
2
3
1
3
2
3
1
1
3
3
2
1
3
1
3
2
2
2
2
1
NAME H.NO AGE SEX(M-1,F-0)CTP MELD-D1/F/UVWE D1 VWF D3 vWf activity D1
THIRUMALAI 053449G 45 1 3 17
RAJA GOPAL REDDY 923890F 49 1 3 29
MD IBRAHIM 071755G 50 1 3 30
RAJMANI SINGH 070180G 45 1 3 30
SURESH CHANDRA SINKU066983G 63 1 3 23
MANSOOR 926237F 39 1 3 20
MAHINDRA AGRWAL 646620F 31 1 3 22
SARAVANAN 926645F 48 1 3 39
RAMESHWAR ORAN 928179F 45 1 3 27
LAXMI BALA DAS 928353F 52 0 3 23
VADIVEL 079658G 38 1 3 35
SIVAKUMAR 928429F 32 1 3 25
HIRAK MONDAL 082366G 36 1 3 23
LAVAKUMAR 928956F 41 1 3 26
ANIL KUMAR SINGH 929379F 45 1 3 21
THIRUMALESH 929531F 34 1 3 33
BALARAMAN 929661F 51 1 3 29
THOMAS MV 092111G 60 1 3 24
VENKATAIYA 097517G 30 1 3 36
LALAN YADAV 925391F 38 1 3 40
MANJUNATH RAJU 931210F 28 1 3 27
MD AQBAL 929139F 55 1 3 37
SACHIN NASKAR 931488F 57 1 3 40
SYED MARIAM 654424C 30 0 3 26
RANJITA SHERPA 932212F 41 0 3 42
DURGA ROY 941455C 43 1 3 26
MURALIDHAR 327546D 39 1 3 36
BISHNUKUMAR GUPTA104833G 46 1 3 20
BALARAMAN 929661F 51 1 3 31
SIVAKUMAR 928429F 33 1 3 26
RAJESH SHARMA 117134G 38 1 3 37
SARAVANA BALAJI 853822F 35 1 3 49
SURIYA CHANDRA RAO753762F 55 1 3 20
THIRUMURUGAN 937832F 37 1 3 19
SHANKAR NAIK 939146F 40 1 3 41
VISHAL SHARMA 939341F 35 1 3 44
KUBER JAISWAL 497313D 58 1 3 30
TINKU RAJGADIA 093001G 32 1 3 21
JAGIR SINGH 725162F 47 1 3 22
ANANDI 158394g 40 0 3 47
MANOJ SAHU 157060G 33 1 3 43
JAYAPAL 717195D 62 1 3 30
ARUMUGAM 947100F 58 1 3 26
PRASAD 945910F 36 1 3 22
DEBDAS ROY 165928G 38 1 3 25
PRABHAKAR 947211F 31 1 3 39
RAVI 946610F 43 1 3 34
SELVAM 947428F 46 1 3 26
NAGENDRA PRASAD SINGH948001F 52 1 3 34
Bhawari devi 948206F 64 0 3 29
vWf activity D3ACLF gradinglactate SOFA TLC PLT HB INR-D1 INR-F/U
1 16 6 13500 225000 9.9 1.51 1.68
1 2.1 8 7000 64000 13 1.74
1 2.2 10 12100 30000 10.3 2.03 1.9
3 1.9 13 12800 35000 8.9 1.82 2.32
0 1.3 4 6700 195000 6.3 1.7 1.5
0 3.2 5 23900 240000 10.6 1.52
1 2.3 7 26500 122000 8.6 1.5 1.8
2 4.2 10 5800 59000 8.6 2.19 3.79
0 1.7 5 40200 119000 10.1 2.43 2.05
1 1.2 6 8350 69000 11.7 2.1 3.4
2 3.7 7 15700 164000 10 2.01 2.14
0 1.9 6 19700 81000 8.7 2.3
1 3.5 5 18400 161000 10.7 1.67
2 1.2 9 8000 30000 8.2 2.52
0 1.7 7 6600 88000 10 1.89
1 1.2 9 42400 71000 6.9 2.34 1.83
1 11 6 14900 90000 6.2 2.44 1.89
1 1.2 5 13100 103000 14.1 1.9
1 1 8 25700 67000 9.1 2.47
3 1.4 14 13600 96000 9.5 3.19
2 1.3 6 12300 144000 12.4 2.16
2 2.4 9 16900 123000 8.5 1.83
2 6.5 9 9100 83000 8.3 2.2
0 1.7 4 6700 243000 10.7 2.16
3 1.9 9 55400 139000 9.5 3.63 1.83
0 1.4 8 7400 82000 11.7 1.99
1 2.7 7 6300 49000 5.3 4.5 2.38
0 1.5 7 9400 98000 8.7 1.67
3 1.4 12 39300 68000 7.1 1.78
0 0.9 7 3700 39000 7.2 1.93
2 1.7 7 18100 164000 7.7 2.17
3 9.8 12 26400 78000 6.7 3.69 1.98
0 0.8 5 11600 102000 9.5 1.75
0 4.3 6 11000 94000 12.1 1.59
3 1.6 11 24800 198000 8.3 2.18
3 1.2 14 14600 92000 10.1 2.33 1.59
3 7.2 7 17500 120000 5.3 2.5
0 3 6 18500 91000 8.9 1.99 1.68
0 1.8 8 14600 61000 8.4 1.55
2 2 5 13300 353000 9.2 10
2 1.8 14 15500 37000 7.9 2.21
1 1.5 7 15000 90000 6.7 1.95
1 1.9 8 12200 70000 8.2 1.99
0 1.2 4 8400 150000 9.5 1.57
0 1.3 5 5000 103000 9.8 1.62
2 1.3 9 12200 121000 12.3 1.68
2 1.4 6 39600 167000 8.5 1.97
0 1.2 5 8200 100000 12.2 2.02
2 3.5 7 10500 76000 10.1 2.77
2 1.7 7 13200 65000 13.4 2.42
BILI-D1 BILI-F/U Cr-D1 Cr - F/U AST-D1 AST-F/U ALT-D1 ALT-F/U ALP
5.3 4.9 1 0.58 75 83 43 62 180
37 36 1.3 3.3 512 102 119
11.4 14 2.05 0.73 40 20 59
21.7 26.7 1.84 0.94 158 117 41 129 255
7.3 1.4 64 17 185
10.8 0.74 83 10 213
21 20 0.5 1.6 168 108 111
25.6 3.7 5.4 66 23 53
11.6 1.23 0.9 55 19 154
8 23 0.93 1 976 333 173
35.7 52 2.2 2.75 154 137 28 37 103
8.4 5.8 1.15 1.6 47 17 110
13 9.6 1.1 2.14 183 54 85
12 0.59 40 15 114
7.2 0.5 74 27 100
17.3 17 1.92 1.21 7 30 158
5 1.98 1.2 48 16 65
15.6 0.67 121 58 152
30.3 1.89 90 29 62
30.7 4.1 130 50 103
23.9 1.03 226 39 149
8.8 4.95 71 30 193
29.4 3.57 701 189 124
21.4 0.81 1485 477 102
20.9 22.57 2.64 0.71 81 99 20 12 113
11.9 1.35 111 18 81
8.8 1.59 0.91 85 30 86
8.2 0.84 153 82 149
7.4 2.87 1.52 70 36 92
5 0.66 37 10 65
29 2.78 2.38 170 14 96
33.4 4.8 1.4 141 24 136
7.4 0.71 98 41 175
7.1 0.86 139 52 166
29.3 4.1 281 68 118
21.8 34.9 5.5 2.4 116 102 18 28 101
5.1 2.1 81 36 44
6.3 8.5 0.56 155 71 124
15.7 0.73 63 26 208
26.8 1.57 317 175 133
21.1 5.5 113 26 83
11.9 2.08 53 18 111
10.8 1.41 126 80 213
17 0.69 55 37 145
31.2 0.9 224 75 102
29.6 4.3 317 46 202
20.6 2.48 77 8 244
22.5 0.8 227 55 135
7.2 2.53 171 23 117
31.5 0.92 95 51 100
ALBUMIN-D1ALB-F/U SIRS(Y-1/N-2)ETIOLOGY(ETHANOL-1,HB/CV-2,CRYPTOGENIC-3,OTHERS-4)NEW ONSET AKINEW ONSET HEBLOOD CULTUREURINE CULTURESBP
1.7 2.2 1 1 0 0 0 0 0
2.7 0 1 1 0 0 0 0
2.4 1 2 0 1 1 0 0
2.3 2.7 1 1 0 1 0 0 0
2.8 0 1 0 0 0 0 0
2.3 1 1 0 0 0 0 0
2.3 1 1 1 1 0 0 1
2.4 1 1 0 0 0 0 1
2.2 1 1 0 0 0 0 0
2 1 3 0 0 0 1 0
2.2 3.6 1 1 0 0 0 0 0
2 1 1 1 0 1 0 1
2.3 1 1 1 0 0 0 0
2 0 1 0 0 0 1 0
2.1 1 1 0 0 1 0 1
2.6 3 1 1 0 0 0 1 1
1.6 1 1 0 0 0 0 0
2.7 1 3 0 0 0 1 0
2.3 1 1 0 0 0 0 0
2.4 1 1 0 0 0 0 0
2.3 1 2 0 0 0 0 1
1.9 1 1 0 0 0 0 0
2 1 3 0 0 1 0 0
3 0 4 0 0 0 0 0
3.4 3.5 1 1 0 0 0 1 0
2.4 1 1 0 0 0 0 0
1.5 1 1 0 0 0 0 1
1.9 1 2 0 0 0 0 1
2.6 1 1 0 0 1 1 1
2.5 1 1 0 0 0 0 1
1.8 1 1 0 0 0 0 0
2.8 1 1 0 0 0 0 0
2.4 0 1 0 0 0 0 0
3.4 1 1 0 0 0 0 0
2.3 1 1 0 0 0 0 0
2.4 3 1 1 0 0 0 0 0
2.1 1 1 0 0 0 0 0
2 1 1 0 0 0 0 1
2 1 1 0 0 1 0 1
2.7 1 3 1 1 0 0 0
2.5 1 1 1 1 0 0 0
2.1 1 1 0 0 0 0 1
2.1 1 1 1 1 0 0 0
2.8 0 1 0 0 0 1 1
2.8 0 1 0 0 0 0 0
3.3 1 1 0 0 0 0 0
2.3 1 1 0 0 0 0 0
2.1 0 1 0 0 0 0 0
1.8 0 2 0 0 0 0 0
3.3 1 3 0 0 0 0 0
AF CULTUREHAV HEV OGD SPLEEN SIZEHSA NO OF DAYSOUTCOME(DEATH-1/DAMA-2/DISCHARGE-3)FFP Y/N(1/0)REMARKS
0 0 0 0 10.7 1 3 0
0 0 0 POST EVL ULCER 22 1 2 1
0 0 0 17.8 1 3 0
0 16.1 1 1 0
0 0 0 ESO VX 10 0 3 0
0 0 0 10 1 3 0
1 0 0 16.5 1 1 0
1 0 0 11.8 1 1 1 AFTER 5 DAYS OBTAINED FFP
0 0 1 9.8 0 3 0
0 0 0 12.4 1 3 1 AFTER 9 DAYS GOT FFP
0 0 0 13 1 1 0
0 0 0 19.5 1 3 0
0 0 0 15.7 1 2 0 AKI RESOLVED AT DAMA
0 0 0 18.1 1 2 0
0 0 0 10.7 1 3 0
0 0 0 15 1 3 1 FFP GIVEN FOR URETHRAL BLEED
0 0 0 12 1 3 1 FFP GIVEN FOR ENDOTHERAPY
0 0 0 14.6 0 3 0
0 0 0 1 1 0
0 0 0 1 2 0
0 0 0 11.4 1 3 0
0 0 0 14.3 1 1 0
0 0 0 1 1 0 FFP GIVEN
0 0 0 11.9 0 4 6 FFP GIVEN FROM D6 -8
0 0 0 13.4 1 3 8 RECEIVED FFP 0N D2 FOR 4 DAYS
0 0 0 14.3 0 3 0
1 0 0 16 1 3 8 RECEIVED ON D2-4
0 0 0 14.3 1 3 0 10 in second admission aftwr which took DAMA
0 0 0 12 1 1 6 FROM D1 but was not continued
0 0 0 19.5 1 3 0
0 0 0 14.7 1 2 0
0 0 0 14.8 1 3 0
0 0 0 11.4 1 3 4 AFETR 5 DAYS OF ADMISSION
0 0 0 11.7 0 3 0
0 0 0 1 1 0
0 0 1 eso vx 14.7 1 3 0
0 0 0 10.1 1 1 4 ON DAY OF ADMISSISON , HAD MASSIVE GI BLEED
1 0 0 10 1 3 0
1 0 0 ESO VX 17.4 1 3 0
0 0 0 12.5 1 4 0
0 0 0 1 2 5 SECOND DAY OF ADMISSION
0 0 0 20.6 1 3 0
0 0 0 9.8 1 2 0
0 0 0 14.9 1 3 0
0 0 0 20 1 3 0
0 0 0 16 1 2 0
0 0 0 14 1 3 0
0 0 0 15 0 3 0
0 0 0 1 2 0
0 0 0 13.2 0 3 0
NO OF DAYS H STAYACLF grading
6
3
28
12
4
15
6
7
5
3
10
5
11
5
3
9
7
6
4
2
4
2
2
11
9
6
6
15
9 candida in blood
11
5
11 RECEIVED 2 PACKED CELLS
6
4
5 I pc given
12
2 2 PACKED CELLS
7
13
5
4 3 PLATELET GIVEN
7 PACKED CELLS 3 GIVEN
7 PRC 1
11
7
10
7
4
4
7
NAME H.NO AGE SEX(M-1,F-0)CTP MELD-D1/F/UVWE D1 VWF D3 vWf activity D1
THIRUMALAI053449G 45 1 3 17 212.11 544.63 128.60
RAJA GOPAL REDDY923890F 49 1 3 29 684.99 722.62 396.55
MD IBRAHIM071755G 50 1 3 30 1249.44 1411.33 819.54
RAJMANI SINGH070180G 45 1 3 30 985.85 805.27 736.29
SURESH CHANDRA SINKU066983G 63 1 3 23 990.86 1137.89 521.98
MANSOOR 926237F 39 1 3 20 982.52 721.90 477.74
MAHINDRA AGRWAL646620F 31 1 3 22 955.22 1156.73 835.43
SARAVANAN926645F 48 1 3 39 693.43 748.72 610.57
RAMESHWAR ORAN928179F 45 1 3 27 739.97 959.34 680.29
LAXMI BALA DAS928353F 52 0 3 23 259.59 278.80 239.94
VADIVEL 079658G 38 1 3 35 687.09 589.52 590.83
SIVAKUMAR928429F 32 1 3 25 369.18 410.90 281.03
HIRAK MONDAL082366G 36 1 3 23 1029.68 746.53 810.07
LAVAKUMAR928956F 41 1 3 26 634.46 597.69 478.03
ANIL KUMAR SINGH929379F 45 1 3 21 639.51 586.98 97.37
THIRUMALESH929531F 34 1 3 33 779.15 739.93 683.50
BALARAMAN929661F 51 1 3 29 525.67 488.76 468.55
THOMAS MV092111G 60 1 3 24 387.79 412.52 300.00
VENKATAIYA097517G 30 1 3 36 710.60 536.72
LALAN YADAV925391F 38 1 3 40 1200.82 1156.92
MANJUNATH RAJU931210F 28 1 3 27 761.35 730.15 589.31
MD AQBAL 929139F 55 1 3 37 1137.37 1060.04
SACHIN NASKAR931488F 57 1 3 40 776.00 631.64
SYED MARIAM654424C 30 0 3 26 264.07 326.28 119.37
RANJITA SHERPA932212F 41 0 3 42 750.78 702.15 675.65
DURGA ROY941455C 43 1 3 26 817.88 843.89 667.90
MURALIDHAR327546D 39 1 3 36 699.17 558.07 116.17
BISHNUKUMAR GUPTA104833G 46 1 3 20 551.44 582.97 408.16
BALARAMAN929661F 51 1 3 31 742.30 798.64 1089.53
SIVAKUMAR928429F 33 1 3 26 150.03
RAJESH SHARMA117134G 38 1 3 37 531.77 334.46 532.01
SARAVANA BALAJI853822F 35 1 3 49 1013.00 963.35 986.27
SURIYA CHANDRA RAO753762F 55 1 3 20 310.73 301.38 201.29
THIRUMURUGAN937832F 37 1 3 19 468.19 411.53 490.25
SHANKAR NAIK939146F 40 1 3 41 1344.39 1053.80 1038.32
VISHAL SHARMA939341F 35 1 3 44 918.37 1032.85 740.25
KUBER JAISWAL497313D 58 1 3 30 778.70
TINKU RAJGADIA093001G 32 1 3 21 1081.97 959.92 711.60
JAGIR SINGH725162F 47 1 3 22 629.51 461.76 492.44
ANANDI 158394g 40 0 3 47 516.98 537.86 220.68
MANOJ SAHU157060G 33 1 3 43 515.49 510.27 395.65
JAYAPAL 717195D 62 1 3 30 515.49 510.27 395.65
ARUMUGAM947100F 58 1 3 26 1346.67 791.59 739.03
PRASAD 945910F 36 1 3 22 526.66
DEBDAS ROY165928G 38 1 3 25 893.24 1005.81 684.41
PRABHAKAR947211F 31 1 3 39 433.95
RAVI 946610F 43 1 3 34 526.68 585.56 269.68
SELVAM 947428F 46 1 3 26 905.10 1169.84 949.11
NAGENDRA PRASAD SINGH948001F 52 1 3 34 1337.84 997.67 1090.16
Bhawari devi948206F 64 0 3 29 684.58 689.78 467.98
vWf activity D3ACLF gradinglactate SOFA TLC PLT HB INR-D1 INR-F/U
468.64 1 16 6 13500 225000 9.9 1.51 1.68
243.93 1 2.1 8 7000 64000 13 1.74
1217.77 1 2.2 10 12100 30000 10.3 2.03 1.9
773.52 3 1.9 13 12800 35000 8.9 1.82 2.32
679.57 0 1.3 4 6700 195000 6.3 1.7 1.5
257.01 0 3.2 5 23900 240000 10.6 1.52
1048.37 1 2.3 7 26500 122000 8.6 1.5 1.8
633.41 2 4.2 10 5800 59000 8.6 2.19 3.79
1005.12 0 1.7 5 40200 119000 10.1 2.43 2.05
260.22 1 1.2 6 8350 69000 11.7 2.1 3.4
331.70 2 3.7 7 15700 164000 10 2.01 2.14
369.01 0 1.9 6 19700 81000 8.7 2.3
511.85 1 3.5 5 18400 161000 10.7 1.67
457.41 2 1.2 9 8000 30000 8.2 2.52
100.30 0 1.7 7 6600 88000 10 1.89
525.00 1 1.2 9 42400 71000 6.9 2.34 1.83
471.50 1 11 6 14900 90000 6.2 2.44 1.89
297.19 1 1.2 5 13100 103000 14.1 1.9
1 1 8 25700 67000 9.1 2.47
3 1.4 14 13600 96000 9.5 3.19
479.22 2 1.3 6 12300 144000 12.4 2.16
2 2.4 9 16900 123000 8.5 1.83
2 6.5 9 9100 83000 8.3 2.2
295.32 0 1.7 4 6700 243000 10.7 2.16
713.09 3 1.9 9 55400 139000 9.5 3.63 1.83
678.52 0 1.4 8 7400 82000 11.7 1.99
132.02 1 2.7 7 6300 49000 5.3 4.5 2.38
544.53 0 1.5 7 9400 98000 8.7 1.67
903.23 3 1.4 12 39300 68000 7.1 1.78
0 0.9 7 3700 39000 7.2 1.93
277.33 2 1.7 7 18100 164000 7.7 2.17
758.45 3 9.8 12 26400 78000 6.7 3.69 1.98
213.64 0 0.8 5 11600 102000 9.5 1.75
438.51 0 4.3 6 11000 94000 12.1 1.59
904.24 3 1.6 11 24800 198000 8.3 2.18
749.32 3 1.2 14 14600 92000 10.1 2.33 1.59
3 7.2 7 17500 120000 5.3 2.5
727.64 0 3 6 18500 91000 8.9 1.99 1.68
224.49 0 1.8 8 14600 61000 8.4 1.55
280.03 2 2 5 13300 353000 9.2 10
424.87 2 1.8 14 15500 37000 7.9 2.21
424.87 1 1.5 7 15000 90000 6.7 1.95
312.03 1 1.9 8 12200 70000 8.2 1.99
0 1.2 4 8400 150000 9.5 1.57
492.44 0 1.3 5 5000 103000 9.8 1.62
2 1.3 9 12200 121000 12.3 1.68
1304.39 2 1.4 6 39600 167000 8.5 1.97
1246.62 0 1.2 5 8200 100000 12.2 2.02
1133.87 2 3.5 7 10500 76000 10.1 2.77
313.05 2 1.7 7 13200 65000 13.4 2.42
BILI-D1 BILI-F/U Cr-D1 Cr - F/U AST-D1 AST-F/U ALT-D1 ALT-F/U ALP
5.3 4.9 1 0.58 75 83 43 62 180
37 36 1.3 3.3 512 102 119
11.4 14 2.05 0.73 40 20 59
21.7 26.7 1.84 0.94 158 117 41 129 255
7.3 1.4 64 17 185
10.8 0.74 83 10 213
21 20 0.5 1.6 168 108 111
25.6 3.7 5.4 66 23 53
11.6 1.23 0.9 55 19 154
8 23 0.93 1 976 333 173
35.7 52 2.2 2.75 154 137 28 37 103
8.4 5.8 1.15 1.6 47 17 110
13 9.6 1.1 2.14 183 54 85
12 0.59 40 15 114
7.2 0.5 74 27 100
17.3 17 1.92 1.21 7 30 158
5 1.98 1.2 48 16 65
15.6 0.67 121 58 152
30.3 1.89 90 29 62
30.7 4.1 130 50 103
23.9 1.03 226 39 149
8.8 4.95 71 30 193
29.4 3.57 701 189 124
21.4 0.81 1485 477 102
20.9 22.57 2.64 0.71 81 99 20 12 113
11.9 1.35 111 18 81
8.8 1.59 0.91 85 30 86
8.2 0.84 153 82 149
7.4 2.87 1.52 70 36 92
5 0.66 37 10 65
29 2.78 2.38 170 14 96
33.4 4.8 1.4 141 24 136
7.4 0.71 98 41 175
7.1 0.86 139 52 166
29.3 4.1 281 68 118
21.8 34.9 5.5 2.4 116 102 18 28 101
5.1 2.1 81 36 44
6.3 8.5 0.56 155 71 124
15.7 0.73 63 26 208
26.8 1.57 317 175 133
21.1 5.5 113 26 83
11.9 2.08 53 18 111
10.8 1.41 126 80 213
17 0.69 55 37 145
31.2 0.9 224 75 102
29.6 4.3 317 46 202
20.6 2.48 77 8 244
22.5 0.8 227 55 135
7.2 2.53 171 23 117
31.5 0.92 95 51 100
ALBUMIN-D1ALB-F/U SIRS(Y-1/N-2)ETIOLOGY(ETHANOL-1,HB/CV-2,CRYPTOGENIC-3,OTHERS-4)NEW ONSET AKINEW ONSET HEBLO D CULTUREURINE CULTURESBP
1.7 2.2 1 1 0 0 0 0 0
2.7 0 1 1 0 0 0 0
2.4 1 2 0 1 1 0 0
2.3 2.7 1 1 0 1 0 0 0
2.8 0 1 0 0 0 0 0
2.3 1 1 0 0 0 0 0
2.3 1 1 1 1 0 0 1
2.4 1 1 0 0 0 0 1
2.2 1 1 0 0 0 0 0
2 1 3 0 0 0 1 0
2.2 3.6 1 1 0 0 0 0 0
2 1 1 1 0 1 0 1
2.3 1 1 1 0 0 0 0
2 0 1 0 0 0 1 0
2.1 1 1 0 0 1 0 1
2.6 3 1 1 0 0 0 1 1
1.6 1 1 0 0 0 0 0
2.7 1 3 0 0 0 1 0
2.3 1 1 0 0 0 0 0
2.4 1 1 0 0 0 0 0
2.3 1 2 0 0 0 0 1
1.9 1 1 0 0 0 0 0
2 1 3 0 0 1 0 0
3 0 4 0 0 0 0 0
3.4 3.5 1 1 0 0 0 1 0
2.4 1 1 0 0 0 0 0
1.5 1 1 0 0 0 0 1
1.9 1 2 0 0 0 0 1
2.6 1 1 0 0 1 1 1
2.5 1 1 0 0 0 0 1
1.8 1 1 0 0 0 0 0
2.8 1 1 0 0 0 0 0
2.4 0 1 0 0 0 0 0
3.4 1 1 0 0 0 0 0
2.3 1 1 0 0 0 0 0
2.4 3 1 1 0 0 0 0 0
2.1 1 1 0 0 0 0 0
2 1 1 0 0 0 0 1
2 1 1 0 0 1 0 1
2.7 1 3 1 1 0 0 0
2.5 1 1 1 1 0 0 0
2.1 1 1 0 0 0 0 1
2.1 1 1 1 1 0 0 0
2.8 0 1 0 0 0 1 1
2.8 0 1 0 0 0 0 0
3.3 1 1 0 0 0 0 0
2.3 1 1 0 0 0 0 0
2.1 0 1 0 0 0 0 0
1.8 0 2 0 0 0 0 0
3.3 1 3 0 0 0 0 0
AF CULTUREHAV HEV OGD SPLEEN SIZEHSA NO OF DAYSOUTCOME(DEATH-1/DAMA-2/DISCHARGE-3)FFP Y/N(1/0)REMARKS
0 0 0 0 10.7 1 3 0
0 0 0 POST EVL ULCER 22 1 2 1
0 0 0 17.8 1 3 0
0 16.1 1 1 0
0 0 0 ESO VX 10 0 3 0
0 0 0 10 1 3 0
1 0 0 16.5 1 1 0
1 0 0 11.8 1 1 1 AFTER 5 DAYS OBTAINED FFP
0 0 1 9.8 0 3 0
0 0 0 12.4 1 3 1 AFTER 9 DAYS GOT FFP
0 0 0 13 1 1 0
0 0 0 19.5 1 3 0
0 0 0 15.7 1 2 0 AKI RESOLVED AT DAMA
0 0 0 18.1 1 2 0
0 0 0 10.7 1 3 0
0 0 0 15 1 3 1 FFP GIVEN FOR URETHRAL BLEED
0 0 0 12 1 3 1 FFP GIVEN FOR ENDOTHERAPY
0 0 0 14.6 0 3 0
0 0 0 1 1 0
0 0 0 1 2 0
0 0 0 11.4 1 3 0
0 0 0 14.3 1 1 0
0 0 0 1 1 0 FFP GIVEN
0 0 0 11.9 0 4 6 FFP GIVEN FROM D6 -8
0 0 0 13.4 1 3 8 RECEIVED FFP 0N D2 FOR 4 DAYS
0 0 0 14.3 0 3 0
1 0 0 16 1 3 8 RECEIVED ON D2-4
0 0 0 14.3 1 3 0 10 in second admission aftwr which took DAMA
0 0 0 12 1 1 6 FROM D1 but was not continued
0 0 0 19.5 1 3 0
0 0 0 14.7 1 2 0
0 0 0 14.8 1 3 0
0 0 0 11.4 1 3 4 AFETR 5 DAYS OF ADMISSION
0 0 0 11.7 0 3 0
0 0 0 1 1 0
0 0 1 eso vx 14.7 1 3 0
0 0 0 10.1 1 1 4 ON DAY OF ADMISSISON , HAD MASSIVE GI BLEED
1 0 0 10 1 3 0
1 0 0 ESO VX 17.4 1 3 0
0 0 0 12.5 1 4 0
0 0 0 1 2 5 SECOND DAY OF ADMISSION
0 0 0 20.6 1 3 0
0 0 0 9.8 1 2 0
0 0 0 14.9 1 3 0
0 0 0 20 1 3 0
0 0 0 16 1 2 0
0 0 0 14 1 3 0
0 0 0 15 0 3 0
0 0 0 1 2 0
0 0 0 13.2 0 3 0
NO OF DAYS H STAY
6
3
28
12
4
15
6
7
5
3
10
5
11
5
3
9
7
6
4
2
4
2
2
11
9
6
6
15
9
11
5
11
6
4
5
12
2
7
13
5
4
7
7
11
7
10
7
4
4
7
